ENHANCED LYOPHILIZED FORMULATIONS INCLUDING HYALURONIC ACID AND PLASMATIC PROTEINS, AND THEIR USES

专利摘要:
The invention relates to lyophilized pharmaceutical formulations comprising plasma proteins or their derivatives, hyaluronic acid or a derivative thereof, and optionally one or more other pharmaceutically active ingredients, such as clonidine or a derivative thereof. , wherein the lyophilized pharmaceutical formulations are characterized by a reconstitution time of less than 15 minutes. The invention further relates to methods of preparing such formulations and their use for the treatment of musculoskeletal diseases such as bone or joint disease.
公开号:BE1027216B1
申请号:E20205332
申请日:2020-05-13
公开日:2021-06-21
发明作者:Jean Didelez；Nadia Stricwant
申请人:Bone Therapeutics；
IPC主号:

专利说明:

'BE2020 / 5332 ENHANCED LYOPHILIZED FORMULATIONS CONTAINING HYALURONIC ACID AND PLASMATIC PROTEINS, AND THEIR USES The invention relates to the therapeutic medical field and relates more particularly to pharmaceutical formulations or kits and their use for the treatment of diseases such as musculoskeletal diseases, and more particularly diseases of the bones or joints.
BACKGROUND Musculoskeletal diseases are a group of diseases that affect bones, muscles, cartilage, tendons, ligaments and other connective tissues. These disorders can develop over time or be the result of overuse of the musculoskeletal system or trauma. Recently, the focus has been on the development of liquid formulations for local administration, and in particular the intra- or periosseous or intra- or peri-articular administration of active pharmaceutical ingredients to avoid systemic side effects (WO2014 / 049063). These liquid formulations may include solvent / detergent treated plasma and a glycosaminoglycan. After administration, the formulations may have a gel consistency, retaining the active pharmaceutical ingredients and gradually releasing them. It is therefore difficult to obtain a reduction in the viscosity of the formulation during injection and to recover the viscosity in situ. Many formulations are unstable in an aqueous environment, even when exposed for a short time and therefore require packaging, storage and shipping in a powdered or lyophilized state to maintain the product stable during its shelf life. However, current lyophilized pharmaceutical formulations suitable for topical administration are characterized by long reconstitution times, resulting in a cumbersome reconstitution process which is not optimal for clinical use. In addition, the slowness of reconstitution introduces a risk of administration of partially reconstituted formulations, resulting in the presence of unsatisfactory concentrations of active pharmaceutical ingredients in the affected part of the body. There is therefore a continuing need for new, lyophilized and / or improved pharmaceutical formulations which have faster reconstitution times.
SUMMARY As shown by the examples which illustrate some representative embodiments of the invention, the present invention relates to improved lyophilized pharmaceutical formulations which have a short reconstitution time (<15 min) and which address one or more of the above-mentioned problems. state of the art. The results are unexpected, among other things because when freeze-drying pharmaceutical formulations comprising hyaluronic acid and plasma proteins known in the art to treat musculoskeletal diseases, a lyophilized product is obtained which is characterized by long reconstitution time, which makes their use in current practice annoying.
The inventors have observed that the formulations, methods and kits of the present invention have one or more advantages over the state of the art. The present invention makes it possible to considerably improve the reconstitution times of the lyophilized formulations, in particular of the lyophilized formulations for the treatment of musculoskeletal diseases. The medical personnel who administer these formulations are no longer limited in their practice by long reconstitution times and the convenience of use of the formulations, methods and kits of the present invention is therefore improved for both patients and medical personnel. In addition, shorter reconstitution times ensure that the optimum active pharmaceutical dosage is provided to the patient, as there is a risk with formulations having longer reconstitution times that only partially reconstituted formulations will be administered to a patient.
A first aspect of the invention relates to a lyophilized pharmaceutical formulation comprising plasma proteins or derivatives thereof and hyaluronic acid or a derivative thereof, wherein the formulation, when reconstituted in a solution aqueous, has a reconstitution time of 15 minutes or less.
Preferably, the invention relates to a lyophilized pharmaceutical formulation comprising lyophilized plasma and hyaluronic acid or a derivative thereof, wherein the formulation, when reconstituted in an aqueous solution, has a reconstitution time of 15 minutes or less and is set up for injection.
Another aspect of the invention relates to a kit comprising (a) a lyophilized pharmaceutical formulation as described herein; (b) a syringe comprising an aqueous solution; and (c) preferably at least one needle. In some cases, the syringe may be a double syringe comprising the lyophilized pharmaceutical formulation as described herein in one compartment and an aqueous solution in a second compartment.
Another aspect of the present invention relates to a process for preparing a lyophilized pharmaceutical formulation as described herein, comprising the following steps: a) mixing plasma proteins or their derivatives, hyaluronic acid or a derivative thereof. ci and an aqueous solution, which makes it possible to obtain a bulk mixture having a concentration of plasma proteins or their derivatives of 20 mg / ml to 50 mg / ml and a concentration of hyaluronic acid or its derivative of 4 mg / ml to 8 mg / ml;
b) sterilizing the bulk mixture by steam sterilization or filtration, thereby obtaining a sterile mixture; and (c) lyophilization of the sterile mixture, thereby obtaining the lyophilized pharmaceutical formulation. Preferably, the invention provides a process for preparing a lyophilized pharmaceutical formulation as described in 1c1, comprising the following steps: (a) mixing plasma and hyaluronic acid or a derivative thereof, which allows to obtain a bulk mixture; (b) sterilizing the bulk mixture by steam sterilization or filtration, resulting in a sterile mixture (c) lyophilization of the sterile mixture, resulting in the lyophilized pharmaceutical formulation; step (a) comprising the steps of (a1) dissolving hyaluronic acid or its derivative in an aqueous solution, thereby obtaining a first solution; (a2) preparing a second solution comprising the plasma and, optionally, an alpha-2 adrenergic receptor agonist, and (a3) mixing the first and the second solution to obtain the bulk mixture. Another aspect of the invention relates to a lyophilized pharmaceutical formulation obtainable or obtainable by a method as described herein. Another aspect of the invention provides the lyophilized pharmaceutical formulation as described herein for use in the treatment of musculoskeletal disease, preferably wherein the lyophilized pharmaceutical formulation is mixed with an aqueous solution prior to administration. The above and other aspects, as well as preferred embodiments of the invention, are described in the following sections and in the appended claims. The object of the appended claims is hereby specifically incorporated into these specifications.
BRIEF DESCRIPTION OF THE FIGURES Figure 1. Visual appearance of three vials comprising a lyophilized pharmaceutical formulation according to one embodiment of the invention. Figure 2. The graph is a representative hydration curve illustrating weight versus time for 5 lyophilized pharmaceutical formulations according to one embodiment of the invention prepared by a method comprising mixing the first solution and the second solution in a 1: 1 (v / v) ratio and with medium molecular weight HA.
‘BE2020 / 5332
DESCRIPTION OF THE PREFERRED EMBODIMENTS In this document, the singular forms "a", "a" and "the" include both singular and plural referents, unless the context clearly indicates otherwise. The terms "comprising", "includes" and "composed of" as used herein are synonymous with "including", "comprising" or "containing", "contains", and are inclusive or not and n 'do not exclude additional members, elements or method steps not recited. These terms also encompass "consisting of" and "consisting essentially of", which have well-established meanings in patent terminology. The recitation of the number ranges by the parameters includes all the numbers and fractions subsumed in the respective ranges, as well as the recited parameters. This applies to number ranges, whether introduced by the expression "from ... to." or the expression "between ... and ..." or another expression. The terms "about" or "approximately", as used herein to denote a measurable value such as a parameter, amount, time duration, etc., are intended to encompass variations from the value. specified, such as variations of +/- 10% or less, preferably +/- 5% or less, more preferably +/- 1% or less, and still more preferably +/- 0.1% or less than the specified value, as long as such variations are appropriate for the execution of the disclosed invention. It should be understood that the value to which the modifier "about" or "approximately" refers is itself also specifically, and preferably, disclosed. While the terms "one or more" or "at least one", such as one or more members or at least one member of a group of members, are clear in themselves, by way of example the term includes in particular a reference to any of said members, or to two or more of said members, such as, for example, any> 3,> 4,> 5,> 6 or> 7 etc. of said members, and up to all of said members In another example, "one or more" or "at least one" may refer to 1, 2, 3, 4, 5, 6, 7 or more. this document to explain the background of the invention. This should not be taken as an admission that any of the items mentioned have been published, known or are part of the common general knowledge in any country on the priority date of the invention. one of the claims. Throughout these specifications, various publications and patents are referenced by an identifying citation. The specifications are incorporated by reference in their entirety. In particular, the teachings or sections of those documents which are specifically referred to herein are incorporated by reference.
Unless defined otherwise, all terms used in the disclosure of the invention, including technical and scientific terms, have the meanings commonly given to them by one of the ordinary skill in the art to which this invention belongs.
Definitions of terms are included for guidance to better appreciate the teaching of the invention.
Where specific terms are defined in relation to a particular aspect of the invention or a particular embodiment of the invention, that connotation or meaning is intended to apply throughout this specification, i.e. to say also in the context of other aspects or embodiments of the invention, unless defined otherwise.
In the following passages, various aspects or embodiments of the invention are defined in more detail.
Each preferred aspect or embodiment thus defined may be combined with any other aspect or embodiment, unless clearly indicated otherwise.
In particular, any characteristic indicated as being preferred or advantageous may be combined with any other characteristic or embodiment indicated as being preferred or advantageous. Reference in this specification to "an embodiment," "embodiment" means that a particular feature, structure or character described in connection with the embodiment is included in at least one embodiment of the present invention. .
Thus, the expressions "in an embodiment" or "in an embodiment" which appear in various places in the present description do not necessarily all refer to the same embodiment, but can do so.
Further, the particular traits, structures or characteristics may be combined in any suitable manner, as would be apparent to those skilled in the art from the present disclosure, into one or more incamations.
Further, while some embodiments described herein include some features, but not others, included in other embodiments, combinations of features of different embodiments are intended to be within the scope. of the invention and form different embodiments, as understood by specialists.
For example, in the appended claims, all of the claimed embodiments can be used in any combination.
Lyophilization of liquid pharmaceutical formulations developed previously, comprising plasma proteins and hyaluronic acid, in particular for the treatment of musculoskeletal diseases (WO2014049063), is characterized by long reconstitution times, which is impractical for a patient. routine clinical use.
As shown in the examples, which illustrate certain representative embodiments of the invention, the inventors have developed improved lyophilized pharmaceutical formulations and methods for obtaining said formulations which have a short reconstitution time (<15 min), thus meeting the requirements of one or more of the aforementioned problems in the art.
© BE2020 / 5332 The terms “lyophilized” or “lyophilized” can be used interchangeably in this document and refer to a condition and / or a state of a sample, of a formulation or of a product obtained by lyophilization. Lyophilization, also called lyophilization or freeze-drying, is a dehydration process that involves freezing the product without destroying the physical structure of the material. Lyophilization includes at least a freezing step and a sublimation step. The sublimation step can include two drying stages: a primary drying stage and a secondary drying stage. Lyophilization can be used for the manufacture of pharmaceuticals and their intermediates. During freezing, the material is cooled to a temperature at which the solid phases , liquid and gas of the material may exist. Active Ingredients of Pharmaceuticals (APIs) can be lyophilized in order to ur obtain a chemical stability allowing storage at room temperature. This method is different from a conventional method of evaporating water using heat. The advantages of lyophilization can be, among others, improved aseptic handling, increased stability of a dry powder, removal of water without excessive heating of the product, and increased stability of the product in the dry state. In general, the quality of a rehydrated and lyophilized product is excellent and does not exhibit inferior (therapeutic) characteristics than a non-lyophilized product.
The terms "pharmaceutical formulation", "pharmaceutical composition" or "pharmaceutical preparation" can be used interchangeably in this document. Likewise, the terms "formulation", "composition" or "preparation" may be used interchangeably herein. In this description, the absolute amounts referred to 1c1 correspond to the amounts present in an administration dose, unless explicitly indicated otherwise.
Preferably, the lyophilized pharmaceutical formulation is a soluble or dissolvable formulation.
The ivophilized pharmaceutical formulation advantageously dissolves when reconstituted in aqueous solution, i.e. all or substantially all, such as at least 90%, at least 95%, at least 96%, at least. at least 97%, at least 98%, at least 99%, at least 99.5% or 100% of the lyophilized pharmaceutical formulation is dissolved or solubilized when reconstituted.
In this document, the term "reconstitution" refers to the process of restoring a dried, lyophilized, dehydrated or concentrated material to its original or liquid state, by the addition of a solvent to the lyophilized material, allowing the The lyophilized material to rehydrate, followed by stirring the mixture of solvent and the lyophilized material. The reconstituted material may or may be part of a product, formulation, sample, raw material or any biological material, but it is certainly not limited to material falling within the common definition. of these terms. Reconstitution can be visually assessed with the naked eye. The [yophilized material is considered to be reconstituted when a homogeneous solution is observed. In particular, a cloudy-looking solution is considered to be well reconstituted.
Reconstruction can also be assessed by impedance-based methods. In these methods, minor changes in the impedance of the reconstitution medium are detected due to dissolution of the solid material during the reconstitution or dissolution process. A double-electrode needle is injected into the diluent and the change in the impedance signal is continuously monitored in the added diluent. It determines the levels of concentration, because the impedance depends on the number and the mobility of the ionic carriers which allow the electric current to flow. The electric current (I) conducted by a liquid containing singularly charged ions can be expressed as I = NqU / L with N as the number of ions in the liquid, q is the elementary charge, u is the average ion mobility, U is the applied potential and L is the length of the conduction path. The electrical resistance can be expressed as R = L / Nqu. The electrical resistance represents the real part of the impedance signal (Z), which also depends on the reactance (X), which in turn depends on the applied AC frequency (f) and the capacitance of the solution (c): Z = VR2 + X2 with X = 1 / (nfc). All components of a yophilisate which dissolve during reconstitution contribute to the change in the impedance signal. The reconstitution end point was set to an impedance change of less than 1 ohm for at least 7 seconds.
The term "aqueous solution" denotes any solution comprising water or in which the solvent is water. Furthermore, the term "aqueous solution" is used to describe solutions having points in common with water or aqueous solutions, without being limited to characteristics such as appearance, odor, color, taste, viscosity, pH, absorbance or physical state at particular temperatures.
The terms "percentage by weight", "percentage by mass", "percentage (%) by weight", "weight%" or "wt%" indicate the mass of a substance relative to the total mass of the formulation (ie (i.e., mass fraction) with a denominator of 100. Unless otherwise indicated,% by weight is given herein based on the total weight of the lyophilized pharmaceutical formulation.
The terms "buffer component", "buffer solution" or "buffer", used interchangeably herein, mean an aqueous solution comprising a mixture of a weak acid and its conjugate base or vice versa. Buffer solutions are characterized by the means they use to maintain the pH of a solution almost constant when limited amounts of strong acids or strong bases are added to the solution. The amount of strong acid or strong base that can be added to the buffer solution before a significant change in pH occurs depends on the specific buffer solution used and is commonly referred to as buffering capacity. The pH of a buffer solution can be estimated using the Henderson-Hasselbalch equation, which is known to one skilled in the art.
As defined herein, the pH of a formulation can be measured using various methods known to those skilled in the art. PH indicators can be used which discolor upon absorption or release of H ’ions, their resulting color being indicative of a certain pH value. It is also possible to use pH meters which measure the difference in electric potential between a pH electrode and a reference electrode. The difference in electrical potential is related to the acidity or pH of the solution.
A first aspect of the present invention provides a lyophilized pharmaceutical formulation comprising plasma proteins or derivatives thereof and hyaluronic acid or a derivative thereof, wherein the formulation, when reconstituted in solution aqueous, has a reconstitution time of 15 minutes or less, preferably 10 minutes or less, more preferably 5 minutes or less. In particular, the lyophilized pharmaceutical formulation comprises lyophilized plasma and hyaluronic acid or a derivative thereof, wherein the formulation, when reconstituted in an aqueous solution, has a reconstitution time of 15 minutes or less. , preferably 10 minutes or less, more preferably 5 minutes or less. Accordingly, one aspect relates to a lyophilized pharmaceutical formulation comprising lyophilized plasma and hyaluronic acid or a derivative thereof, wherein the formulation, when reconstituted in an aqueous solution, has a reconstitution time of 15. minutes or less, preferably 10 minutes or less, more preferably 5 minutes or less.
The terms "lyophilized pharmaceutical formulation", "lyophilized formulation", "lyophilized wafer", "wafer" and "formulation" are used interchangeably in this document and refer to the lyophilized pharmaceutical formulation as taught in the present document. this document.
In embodiments, the invention provides a lyophilized pharmaceutical formulation comprising plasma proteins or derivatives thereof and hyaluronic acid or a derivative thereof, wherein the formulation comprises from about 30% to 30%. about 80% by weight of plasma proteins or derivatives thereof, wherein the formulation, when reconstituted in aqueous solution, has a reconstitution time of 15 minutes or less and is configured for injection.
"Plasma proteins", as defined 1c1, refer to proteins derived from plasma, or proteins which may be present and / or detected in blood plasma. Plasma proteins are not limited to human plasma proteins, except as explicitly stated in this document. Plasma proteins included in the formulation
Pharmaceutical BE2020 / 5332 may include any protein or modified protein naturally occurring from plasma. In the present document, the term "plasma proteins" also includes synthetic plasma proteins or derivatives of plasma proteins.
Terms "derived from plasma proteins" or "derived from plasma proteins" as described herein refer to unique proteins derived from plasma, such as any of the plasma proteins listed herein. In some embodiments, plasma proteins or their derivatives can be derived from plasma. In some cases, plasma proteins or their derivatives can be derived from lyophilized plasma. In some cases, plasma proteins or their derivatives can be part of lyophilized plasma. In some cases, the lyophilized plasma comprises plasma proteins or derivatives thereof. The term "plasma" is defined in a conventional manner. The plasma can be any plasma as conventionally defined, such as fresh plasma, fresh frozen plasma, frozen thawed plasma, or cryoprecipitate, cryogenic supernatants or frozen plasma concentrates, as well as dilution products of these. The term "plasma" also includes PRP (Platelet Enriched Plasma) or a plasma substitute. Plasma is usually obtained from a whole blood sample, supplied or contacted with an anticoagulant, (eg, heparin, citrate, oxalate or EDTA). Then, the cellular components of the blood sample are separated from the liquid component (plasma) by a suitable technique, usually by centrifugation. The term “plasma” therefore designates a composition which does not form part of a human or animal body. In some embodiments, the plasma can be from warm blooded animals, such as mammals, such as humans. The term "platelet rich plasma (PRP)" refers to plasma that has been enriched for platelets. In general, PRP can contain about 1.0x10 ° platelets / µl, while the concentration of platelets in whole blood can be about 1.5x10 ° to 3.5x10 ° / µl. Accordingly, plasma as provided herein may contain less than about 1.5x10 ° to 1.0x10 ° platelets / µl. In mcarnations, the plasma is not a platelet rich plasma. It is not subjected to further enrichment or fractionation steps before being used in the process described herein for the preparation of a lyophilized pharmaceutical formulation. In the constructs, the plasma may have a composition which is substantially the same as the plasma obtained conventionally, for example as described above. In some cases, the lyophilized pharmaceutical formulation comprises lyophilized plasma. In some cases, the lyophilized pharmaceutical formulation comprises lyophilized plasma, which in turn comprises plasma proteins or derivatives thereof. In some cases, the lyophilized pharmaceutical formulation comprises lyophilized plasma treated with solvent / detergent (S / D). In some instances, the lyophilized pharmaceutical formulation comprises plasma proteins which are solvent / detergent (S / D) treated plasma proteins. In some cases, S / D plasma proteins are derived from warm-blooded animals, such as mammals,
like humans.
In some embodiments, the plasma can be S / D plasma.
In some cases, the plasma proteins are solvent / detergent (S / D) treated plasma proteins, preferably human S / D plasma proteins.
In some cases, plasma proteins or their derivatives can be derived from S / D plasma.
In some cases, plasma proteins or their derivatives may be part of lyophilized S / D plasma.
In some cases, lyophilized S / D plasma comprises plasma proteins or derivatives thereof.
The terms "solvent / detergent treated plasma", "S / D treated plasma" or "S / D plasma" generally refer to decellularized plasma obtainable or obtained by a method comprising the following steps (a) treating the plasma with a solvent and a detergent and (b) filtering the treated plasma with a solvent / detergent.
The plasma to be treated in step (a) can be any plasma as defined conventionally, such as fresh plasma, fresh frozen plasma, frozen thawed plasma, or cryoprecipitate, cryoprecipitate supernatants or frozen plasma concentrates as well. as the dilution products thereof.
Plasma is usually obtained from a whole blood sample, or from a sample obtained by apheresis.
The solvent used for the preparation of the S / D plasma is preferably a dialkylphosphate or a trialkylphosphate, both of which have alkyl groups which contain 1 to 10 carbon atoms, in particular 2 to 10 carbon atoms.
Examples of solvents may include tri- (n-butyl) phosphate, tri- (t-butyl) phosphate, tri- (n-hexyl) phosphate, tri- (2-ethylhexyl) phosphate or tri- ( n-decyl) phosphate.
Tri- (n-butyl) phosphate is a preferred solvent.
The solvent such as di- or trialkylphosphate for use in treatment step (a) is preferably employed in an amount ranging from about 0.01 mg / ml to about 100 mg / ml, and more preferably about 0.1 mg / ml to about 10 mg / ml.
In other words, the di- or trialkylphosphates for use in processing step (a) are preferably used in an amount between about 0.001% w / v and about 10% w / v, and more preferably between about 0.01% w / v and about 1% w / v.
The detergent used for the preparation of the S / D plasma is preferably a non-toxic detergent.
The nonionic detergents contemplated include those which disperse at room temperature at least 0.1% by weight of the fat in an aqueous solution containing the same when there BE2020 / 5332 is introduced 1 gram of detergent per 100 ml of solution. . Among the examples of detergents, mention may be made of polyoxyethylene derivatives of fatty acids, partial esters of sorbitol anhydrides, for example, the products known commercially under the names of "Tween® 80", "Tween® 20" and "polysorbate 80" and oil-soluble nonionic detergents, such as those sold commercially under the trademark "Triton" X 100 "(oxyethylated alkylphenol). Also contemplated are sodium deoxycholate as well as" Zwittergents "which are synthetic zwitterionic detergents known as "sulfobetaines" such as N-dodecyl-N, N-methyl-2-ammonio-l ethane sulfonate and its congeners or nonionic detergents such as octyl-beta. D-Glucopyranoside The amount of detergent can vary from about 0.001% v / v to about 10% v / v, preferably from about 0.01% v / v to 1.5% v / v.
The solvent and detergent treatment is preferably carried out at a temperature between -5 ° C and 70 ° C, preferably between 0 ° C and 60 ° C. The duration of this treatment (contact) is at least 1 minute, preferably at least 1 hour and generally from 4 to 24 hours. The treatment is normally effective at atmospheric pressure, although sub-atmospheric and super-atmospheric pressures can also be used. Normally, after the treatment, the solvent such as trialkylphosphate and detergent are removed. The solvent and the detergent can be removed by any suitable technique to separate the solvent and the detergent from the plasma. When a nonionic detergent is used with the solvent, such as trialkylphosphate, they can be removed by: (1) diafiltration using microporous membranes such as TEFLON which retain plasma proteins; (2) absorption of desired plasma components on chromatographic or affinity chromatographic media; (3) precipitation, for example by salting plasma proteins; (4) lyophilization, etc. Solvents such as dialkylphosphate or trialkylphosphate can be removed as follows: a) Removal of antihemophilic factor (FHA) can be accomplished by precipitation of FHA with 2.2 molar (M) glycine and sodium chloride 2 , 0 M b) Removal of fibronectin can be accomplished by binding fibronectin on an insolubilized gelatin column and washing the bound fibronectin without reagent.
Filtration step (b) is usually performed with a 1 µm filter to remove cells and debris, followed by sterile filtration with a 0.2 µm filter.
In some models, the S / D treatment includes at least one solvent and / or oil detergent extraction step. Preferably, the oil is soybean or castor oil. In some cases, the plasma is treated by an additional process before or after the S / D treatment. In other cases, these methods may include ultraviolet (UV) radiation alone or in combination with a photochemical active agent. UV radiation can be chosen from the group comprising UVA (wavelength between about 315 nm and about 400 nm), UVB (wavelength between about 280 and about 315 nm), UVC (wavelength between about between 100 nm and 280 nm). Photochemical active agents can be selected from a group comprising psoralens, for example, amotosalen and riboflavin.
In some cases, plasma may be processed by the INTERCEPT System, as known to a person skilled in the art and described in the literature (Update on Treatment of Plasma Pathogen Inactivation, Using the INTERCEPT Blood System System: Current position on methodological, clinical and regulatory aspects.
Irsch J., Transfus.
Apher.
Sci, 2015). The term "S / D plasma" includes plasma having a reduced concentration or activity of plasmin inhibitor, such as a level of plasmin inhibitor of 0.60 IU / ml or less or less than or equal to 0. , 50 IU / ml, for example a level of plasmin inhibitor of between 0.20 and 0.30 IU / ml, more precisely between 0.22 and 0.25 IU / ml.
Compared to fresh frozen plasma (FFP), S / D plasma may include a reduced amount and / or activity of one or more of the following: plasmin inhibitor, protein S, factor XI, factor V, factor VIII, factor X, antiplasmin a2, anti-trypsin, von Willebrand factor (VWF), and von Willebrand protease (VWFCP), also called disintegrin and metalloproteinase with a pattern of thrombospondin type 1, member 13 (ADAMTS-13), factor alpha tumor necrosis (TNFa), interleukin 8 (IL-8), mterleukin 10 (IL-10) (Benjamin and McLaughlin, 2012, Svae et al., 2007; Beeck and Hellstern, 1998; Doyle et al, 2003; Mast et al., 1999, Theusmger et al, 2011) and / or may include an increased amount and / or activity of factor VII (Doyle et al, 2003). Plasma, such as S / D plasma, can be heat inactivated as required by the art, especially to remove complement.
When current pharmaceutical formulations use plasma, such as S / D plasma, autologous for the subject to be treated, it may be unnecessary to inactivate plasma, such as S / D plasma, by heat.
When the plasma, such as S / D plasma, is at least partially allogeneic to the subject to be treated, it may be advantageous to inactivate the plasma by heat, such as S / D plasma.
Plasma, such as S / D plasma, can be autologous for the subject to be treated.
The term "autologous" in reference to plasma, such as S / D plasma, indicates that plasma, such as S / D plasma, is obtained from the same subject which is to be contacted or treated with the plasma, such as S / D plasma.
In addition, plasma, like S / D plasma, can also be "homologous" or "allogeneic" to the subject to be treated, that is to say obtained from one or more (grouped) subjects other than the subject. to contact or treat with plasma, such as S / D plasma.
Allogeneic plasma, such as S / D plasma, is advantageously commercially available and therefore constitutes an unlimited source of plasma.
In some cases, the plasma, such as S / D plasma, can come from warm-blooded animals, such as mammals, such as humans.
© BE2020 / 5332 In some cases, the plasma protein (s) may belong to the non-limiting group consisting of albumin, globulin, fibrinogen, regulatory proteins and coagulation factors.
In other cases, the plasma proteins may be one or more of the following prealbumin (transthyretin), alpha 1 antitrypsin, alpha 1 acid glycoprotein, alpha 1 fetoprotein, alpha 2 macroglobulin, gamma globulins, beta 2 microglobulin, haptoglobulin, ceruloplasmin , complement component 3, supplement component 4, C-reactive protein (CRP), lipoproteins (chylomicron, high density lipoprotein, low density lipoprotein and very low density lipoprotein), transferrin, prothrombin, mannose binding lectin, lectin Mannan Binding Protein (MBL) or Mannan Binding Protein (MBP). In other cases, the natural composition of plasma proteins can be kept as is and used as a component of the pharmaceutical formulation.
Plasma compositions and plasma protein concentration ranges are well known to those skilled in the art.
In other cases, a plasma protein or group of plasma proteins may have been separated from a collection of plasma proteins to be included in the formulation.
In other cases, a plasma protein or group of plasma proteins may have been separated from a collection of plasma proteins to be excluded from the pharmaceutical formulation.
Plasma or plasma proteins can come from a single blood donor.
In other cases, plasma or plasma proteins can be obtained from a mixture of plasma proteins from at least two donors.
In other cases, the plasma can be supplemented with additional proteins.
In other forms, one or more plasma proteins contain post-translational modifications.
In still other cases, post-translational modifications to one or more plasma proteins have been introduced after separation of cellular components from plasma.
In other cases, the relative concentration of at least one plasma protein was altered before or after the separation of components - cellular.
In some cases, plasma proteins are derived from blood donors of a certain age.
In other cases, plasma proteins are derived from blood donors whose genotype is known.
In other cases, plasma proteins are derived from serum or include serum proteins.
For example, the serum can be allogeneic or autologous to the subject receiving the formulation.
Preferably, the serum may be human serum, so that pharmaceutical formulations further comprising human serum are particularly suited for administration to human subjects.
In some cases, serum can be obtained from plasma treated with a solvent / detergent.
The S / D plasma can be suitably processed to counteract the action of the anticoagulant, for example to allow the conversion of fibrinogen to fibrin and the formation of the clot.
In some incamations, the serum can come from warm-blooded animals, such as mammals, such as humans.
In the embodiments, the lyophilized pharmaceutical formulation comprises lyophilized serum.
Thus, in certain particular aspects or embodiments, the lyophilized pharmaceutical formulation comprises lyophilized serum and hyaluronic acid or a derivative thereof, wherein the formulation, when reconstituted in an aqueous solution, has a reconstitution time of 15 minutes or less, preferably 10 minutes or less, more preferably 5 minutes or less.
Accordingly, one aspect relates to a lyophilized pharmaceutical formulation comprising lyophilized plasma and / or lyophilized serum, and hyaluronic acid or a derivative thereof, wherein the formulation, when reconstituted in an aqueous solution, has a reconstitution time of 15 minutes or less, preferably 10 minutes or less, more preferably 5 minutes or less.
In incarnations, the formulation is set up for injection.
In some instances, the formulation comprises from about 70% to about 99.9% by weight of lyophilized plasma and / or serum.
In some instances, the formulation comprises about 70 to 99% by weight of lyophilized plasma and / or serum, preferably about 75 to 99% by weight or about 80 to 97% by weight of lyophilized plasma and / or serum.
For example, the formulation comprises from about 70% to about 95% by weight or from about 70% to about 90% by weight of lyophilized plasma and / or serum.
In some embodiments, the lyophilized serum comprises plasma proteins or derivatives thereof.
In some cases, the formulation comprises at least about 30% by weight of plasma proteins or their derivatives, for example at least about 40% by weight, at least about 50% by weight, at least about 60%, at least about 70%. % by weight, at least about 80% by weight, or at least about 90% by weight of plasma proteins or their derivatives.
In some cases, the formulation comprises between 30% and 90% by weight of plasma proteins or their derivatives.
In some cases, the formulation comprises about 30% to about 80% by weight of plasma proteins or their derivatives, about 40% to about 75% by weight, in particular about 50% to about 70% by weight, or about 55%. to about 60% by weight of plasma proteins or their derivatives.
For example, the formulation comprises from about 40% to about 70% by weight or from about 45% to about 65% by weight of plasma proteins or their derivatives.
Preferably, the plasma proteins are solvent / detergent (S / D) treated plasma proteins, particularly human S / D plasma proteins.
In some instances, plasma proteins or their derivatives are included in the pharmaceutical formulation at a weight percent of about 30% to about 80%, preferably about 40% to about 75%, more preferably about 50%. to about 70%, for example about 55% to about 65%.
N BE2020 / 5332 The terms "hyaluronic acid" or "HA" can be used interchangeably with "hyaluronan", "hyaluronate" or "sodium hyaluronate" or "sodium hyaluronate". The term "hyaluronic acid" denotes an anionic, unsulfated polymer of disaccharides composed of D-glucuronic acid and N-acetyl-D-glucosamine, linked by alternating P-1,4 and B-1,3 glycosidic bonds. . Hyaluronic acid and its derivatives belong to the group of glycosaminoglycans. In particular, the lyophilized pharmaceutical formulation comprises fibers of hyaluronic acid or one of its derivatives. The term "glycosaminoglycan" or "mucopolysaccharides" denotes unbranched polar polysaccharides consisting of a repeating disaccharide unit. Due to their water-attracting properties, they can be used as a lubricant or as a shock absorber. As used herein, a lubricant works by reducing the friction between the surfaces in contact with each other.
In some cases, the hyaluronic acid derivative is a salt of hyaluronic acid, an ester of hyaluronic acid with an alcohol of the aliphatic, heterocyclic or cycloaliphatic series, or a sulfated form of hyaluronic acid.
Hyaluronic acid derivatives include, among others, hyaluronate salts such as sodium hyaluronate or an ester of hyaluronic acid with an alcohol of the aliphatic, heterocyclic or cycloaliphatic series, or a sulfated form of hyaluronic acid. or a combination of agents comprising hyaluronic acid. Without limitation, suitable derivatives can be salts of hyaluronic acid, such as, preferably, sodium hyaluronate.
In certain applications of the formulation or process as described herein, hyaluronic acid or a derivative thereof comprises, consists essentially of, or consists of fibers having a molecular weight of 0.2 MDa to 4.5 MDa, preferably 0.5 MDa to 1.5 MDa or 0.5 MDa to 1.2 MDa.
The terms "molecular weight (relative)" and "molecular weight" can be used interchangeably in this document and refer to the mass of a molecule.
In particular, hyaluronic acid or a derivative thereof may have a molecular weight ranging from about 0.2 MDa to about 8 MDa or more, such as for example from about 0.2 MDa to about 6 MDa or d about 0.4 MDa to about 6 MDa. In other particular cases, the hyaluronic acid or a derivative thereof may have a molecular weight ranging from 0.2 MDa to about 4.5 MDa or from about 0.4 MDa to about 4.5 MDa. In still other cases, hyaluronic acid or a derivative thereof may have a molecular weight ranging from about 0.2 MDa to about 2.0 MDa, and more particularly from 0.4 MDa to about 1.5 MDa. , and even more particularly from about 0.5 MDa to about 1.2 MDa. In some embodiments, hyaluronic acid or a derivative thereof may have a molecular weight ranging from about 0.6 MDa to about 1.0 MDa. Advantageously,
lo BE2020 / 5332 lyophilized pharmaceutical formulations comprising hyaluronic acid or a derivative thereof having a molecular weight ranging from about 0.5 MDa to about 1.2 MDa, preferably from about 0.6 MDa to approximately 1.0 MDa, provide a homogeneous formulation for injection when reconstituted. Further, the reconstituted formulations have a satisfactory viscosity for injection and provide sufficient viscosity in situ after administration. Accordingly, another aspect provides a lyophilized pharmaceutical formulation comprising lyophilized plasma and hyaluronic acid or a derivative thereof, wherein the hyaluronic acid or its derivative comprises fibers having a molecular weight of 0.5 MDa. at 1.2 MDa, wherein the formulation, when reconstituted in an aqueous solution, has a reconstitution time of 15 minutes or less. Preferably, the hyaluronic acid or a derivative thereof comprises fibers having a molecular weight of 0.6 MDa to 1.0 MDa. Such lyophilized pharmaceutical formulations make it possible to obtain a homogeneous formulation for injection after reconstitution.
Preferably, the HA or its derivative has a low polydispersity index (PDI), which is a measure of the uniformity of the population of polymers or, in other words, of the distribution of molecular weights in a population of polymers, and is calculated by the ratio between the weight average and the numerical average of the molecular weight of the polymer, as known to those skilled in the art. More particularly, HA or its derivative has a polydispersity index of about 1.50 or less, such as about 1.40 or less, about 1.30 or less, about 1.20 or less, or 1, 10 or less.
In some embodiments, a single polymeric form of hyaluronic acid or a derivative thereof is used. In other cases, different lengths of hyaluronic acid or its derivatives can be used at different relative concentrations in a preferred formulation. In other cases, different derivatives of hyaluronic acid are present in the formulation. In some cases, the hyaluronic acid or its derivative is modified during the preparation of the pharmaceutical formulation.
In some cases, hyaluronic acid can be present in the pharmaceutical formulation in combination with at least one derivative of hyaluronic acid. Combinations of hyaluronic acid and derivatives can include, but are not limited to, hyaluronic acid and, for example, a salt of hyaluronic acid, for example an ester of hyaluronic acid, for example an alcohol of the aliphatic, for example heterocyclic or cycloaliphatic series of hyaluronic acid, for example any sulphated form of hyaluronic acid. In some cases, more than two hyaluronic acid derivatives may be present in the pharmaceutical formulation.
U BE2020 / 5332 Also provided are derivatives of hyaluronic acid which bind to all cellular receptors for hyaluronic acid, including, but not limited to the CD44 receptor, the receptor for cell-mediated motility. HA (RHAMM) and intercellular adhesion molecule 1 ([CAM-1). In some cases, the lyophilized pharmaceutical formulation corresponding to an administration dose comprises from 1 mg to 100 mg of hyaluronic acid or a derivative thereof. For example, the formulation corresponding to an administration dose may comprise from 2 mg to 90 mg, or from 5 to 75 mg of hyaluronic acid or a derivative thereof, preferably from 2 mg to 50 mg of hyaluronic acid or a derivative thereof, more preferably 5 mg to 45 mg, 5 mg to 40 mg, 5 mg to 35 mg, 5 mg to 30 mg or 5 mg to 25 mg of hyaluronic acid or a derivative thereof.
In some cases, the lyophilized pharmaceutical formulation comprises between 5.0% and 20.0% by weight of hyaluronic acid or a derivative thereof. For example, the lyophilized pharmaceutical formulation comprises from about 7.5% to about 15.0% by weight or from about 10.0% to about 12.5% by weight of hyaluronic acid or a derivative thereof. -this.
In some cases, the lyophilized pharmaceutical formulation comprises at least one additional glycosaminoglycan, in which the glycosaminoglycan is selected from the group consisting of hyaluronic acid and its derivatives, a proteoglycan and its derivatives, a chondroitin sulfate, a keratan sulfate, a chitosan and its derivatives, a chitin and its derivatives. In other forms of incorporation, more than one additional glycosaminoglycan may be present in the formulation.
The term "chondroitin sulfate" refers to a disaccharide polymer composed of N-acetylgalactosamine and glucuronic acid, each of which may be sulfated in varying positions and amounts. Chondroitin sulfate can be chosen from chondroitin 4-sulfate, chondroitin 6-sulfate, chondroitin 2,6-sulfate, chondroitin 4,6-sulfate.
The Ivophilized formulation as contemplated herein is generally a pale white-yellow cake. The Ivophilized formulation as contemplated herein is a sterile wafer.
The "reconstitution time" as used 1c1 refers to the time between when an aqueous solution is added to the lyophilized formulation (e.g., added above, inside or below. the ivophilized formulation) and when a homogeneous reconstituted product is obtained. Reconstitution is preferably carried out by adding an aqueous solution to the lyophilized formulation, while awaiting hydration of the lyophilized formulation, and then mixing the rehydrated formulation to obtain a homogeneous reconstituted product. Mixing can be done by rolling the vial (eg between hands or mechanically) or by shaking the vial up and down (eg by hand or mechanically). Preferably, the IS BE2020 / 5332 lyophilized formulation is hydrated when all or almost all, for example at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or 100% of the lyophilized formulation has absorbed the aqueous solution.
In some embodiments, reconstitution is achieved by mixing the lyophilized formulation with an aqueous solution such as water suitable for injection.
In other cases, reconstitution may be aided by agitation of the solvent-lyophilized formulation mixture, for example by stirring, shaking, decanting, inverting, inverting or rotating the vial containing the pharmaceutical formulation.
In other cases, reconstitution takes place immediately prior to administration of the formulation to a patient.
In still other forms of administration, at least one additional manipulation precedes administration.
In other forms of administration, reconstitution is at least partially obtained in a syringe.
Without limitation, the reconstitution time of the lyophilized pharmaceutical formulation may be about 15 minutes (min) or less, about 12 min or less, about 10 min or less, about 8 min or less, d '' about 7 min or less, about 6 min or less, about 5 min or less, about 4.5 min or mons, about 4 min or less, about 3.5 min or less , about 3 min or less, about 2.5 min or less, about 2 min or less, about 1.5 min or less, or about 1 min or less.
The reconstitution time is referred to herein as the time between the time of adding an aqueous solution to the lyophilized formulation and the time when the complete lyophilized product is dissolved, as concluded by evaluation by the naked eye or by impedance measurements.
In other cases, the reconstitution time can be further improved by physical agitation of the vial containing the pharmaceutical formulation.
In some cases, the reconstitution time of the lyophilized pharmaceutical formulation can be between 2 seconds and about 15 minutes, between 10 seconds and 15 minutes, between 30 seconds and 10 minutes, between 1 minute and 8 minutes, between 2 minutes and 8 minutes, between 4 minutes and 8 minutes, or between 4 minutes and 6 minutes.
In some cases the lyophilized pharmaceutical formulation has a density of between 0.04 g / cm * and 0.08 g / cm}, or between 0.05 g / cm ° and 0.07 g / cm ', such as for example a density of 0.062 g / cm °. The density of the lyophilized pharmaceutical formulation can be determined (eg calculated) by dividing the weight of the lyophilized pharmaceutical formulation by the volume of the lyophilized pharmaceutical formulation.
The weight can be calculated by subtracting the weight of the empty vial from the weight of the vial containing the lyophilized cake.
The volume can be determined by measuring the dimensions of the lyophilized cake and calculating the volume.
For example, the lyophilized pancake
BE2020 / 5332 can have a cylindrical shape, and the volume can be determined by measuring the height and diameter of the freeze-dried cake, and calculating the volume.
In embodiments, hyaluronic acid or its derivative may have a molecular weight ranging from about 0.5 MDa to about 1.2 MDa, and the lyophilized pharmaceutical formulation may have a density between 0.04 g / cm and 0 , 08 g / cm '. In some cases, hyaluronic acid or a derivative thereof may have a molecular weight ranging from about 0.6 MDa to about 1.0 MDa, and the lyophilized pharmaceutical formulation may have a specific gravity of between 0.04 g. / cm 'and 0.08 g / cm *. In some instances, the lyophilized pharmaceutical formulation comprises from about 30% to about 80% by weight plasma protein and from about 5.0% to about 20.0% by weight of hyaluronic acid or its derivative, hyaluronic acid or its derivative. derivative has a molecular weight of between about 0.5 MDa and about 1.2 MDa, and the lyophilized pharmaceutical formulation has a density of between 0.04 g / cm 2. and 0.08 g / cm ’. In some instances, the lyophilized pharmaceutical formulation comprises from about 30% to about 80% by weight plasma protein and from about 5.0% to about 20.0% by weight of hyaluronic acid or a derivative thereof. The hyaluronic acid or a derivative thereof has a molecular weight of between about 0.6 MDa and about 1.0 MDa, and the lyophilized pharmaceutical formulation has a density of between 0.04 g / cm. and 0.08 g / cm ’. These lyophilized pharmaceutical formulations have a satisfactory reconstitution time, for example a reconstitution time of about 15 minutes (min) or less, about 10 mm or less, about 5 min or less, or about 2 min. or less, while having a viscosity after reconstitution which allows easy administration by injection and ensures sufficient lubricating action after administration. Therefore, one aspect relates to a lyophilized pharmaceutical formulation comprising lyophilized plasma and hyaluronic acid or a derivative thereof, wherein the hyaluronic acid or its derivative has a molecular weight of from about 0.5 MDa to. about 1.2 MDa, in particular a molecular weight ranging from about 0.6 MDa to about 1.0 MDa, and the formulation has a density of between 0.04 g / cm and 0.08 g / cm ’. In embodiments, the formulation comprises about 30% to about 80% by weight plasma protein and about 5.0% to about 20.0% by weight hyaluronic acid or a derivative thereof. In some versions, the residual moisture percentage of the formulation after lyophilization is about 5.0% or less, about 4.0% or less, about 3.0% or less, about 2 , 5% or less. After reconstitution of the lyophilized formulation as contemplated herein, the reconstituted formulation is a yellow, sterile, non-pyrogenic, viscoelastic homogeneous solution. The term "non-pyrogenic" refers to the absence of feverish or heat-producing properties of the formulation. "Viscoelastic" or "viscoelasticity" is the property of materials which exhibit both viscous and elastic characteristics when they undergo deformation. In some cases, the reconstituted pharmaceutical formulation may be characterized by a viscosity of about 100 cP or more, about 200 cP or more, about 250 cP or more, for example between 200 cP and 500 cP or between 250 cP. and 400 cP. Such a viscosity advantageously allows easy administration by injection, while ensuring sufficient lubricating action after administration. Accordingly, another aspect provides a lyophilized pharmaceutical formulation comprising lyophilized plasma and hyaluronic acid or a derivative thereof, wherein the formulation, when reconstituted in an aqueous solution, has a reconstitution time of. 15 minutes or less, and wherein the reconstituted pharmaceutical formulation is characterized by a viscosity of between 200 cP and 500 cP; preferably with a viscosity of between 250 cP and 400 cP. Such lyophilized pharmaceutical formulations, after reconstitution, advantageously allow easy administration by injection, while providing sufficient lubricating action after administration.
The term "viscosity" refers to a measure of a fluid's resistance to strain at a given rate.
The viscosity can be determined by a viscometer. For example, viscosity can be assessed using a microVISC "" viscometer (RheoSense, CA, USA), depending on the supplier's method. For example, a sensor cartridge, for example HB02, can be placed in the viscometer Next, the sample can be loaded into a disposable pipette which is then mounted on the viscometer Advanced parameters can be one or more of the following: Shear rate = 111.6 s *: Measuring volume = 30 µl; Priming volume = 15 µl; Dwell time = 5 s; and Sensor range = 60 to 5000 cP. Since temperature is a well known parameter that influences viscosity, each measurement should preferably be taken at 25.0 + 0 , 1 ° C. Before each use of the microVISC "", the viscosity of a reference oil can be measured to assess the calibration of the equipment.
The measuring chip may contain a borosilicate glass rectangular slit flow channel, with a uniform cross section. The sample can be injected at a constant rate through the flow channel where several pressure sensors mounted in the base monitor the pressure drop from inlet to outlet. The pressure drop can be correlated with the shear stress at the boundary wall. The shear rate and shear stress can be directly related to the geometry of the rectangular slot and the flow rate which allows viscosity to be measured. For example, a VROC® chip can assess viscosity by measuring the pressure drop as a liquid flows through its rectangular slit microfluidic channel. Viscosity data can be exported into the microVISC "" control software
2.0.
A1 BE2020 / 5332 In embodiments, the lyophilized pharmaceutical formulation can be reconstituted in the aqueous solution at a rate of from about 10 ml to about 14 ml of the aqueous solution per gram of the formulation.
In the case of implementation, the lyophilized pharmaceutical formulation can be reconstituted in the aqueous solution at a rate of from about 11 ml to about 13 ml of the aqueous solution per gram of formulation.
For example, the lyophilized pharmaceutical formulation can be reconstituted in the aqueous solution at a rate of about 12 ml of aqueous solution per gram of formulation.
A unit dose of the lyophilized pharmaceutical formulation (eg, generally about 190 mg to 230 mg) can generally be reconstituted in a volume of 2.4 ml of an aqueous solution.
After reconstitution of the lyophilized formulation, the viscosity of the reconstituted formulation can be determined.
In the embodiments, the lyophilized pharmaceutical formulation, when reconstituted in an aqueous solution in an amount of from about 10 ml to about 14 ml of the aqueous solution per gram of the formulation, is characterized by a viscosity of between 200 cP and 500 cP; preferably with a viscosity of between 250 cP and 400 cP.
In preparations, the lyophilized pharmaceutical formulation, when reconstituted in an aqueous solution in an amount of from about 11 ml to about 13 ml of the aqueous solution per gram of the formulation, is characterized by a viscosity of between 200 cP and 500 cP. cP; preferably with a viscosity of between 250 cP and 400 cP.
In the incorporated products, the lyophilized pharmaceutical formulation, when reconstituted in an aqueous solution at about 12 ml of aqueous solution per gram of formulation, is characterized by a viscosity of between 200 cP and 500 cP; preferably with a viscosity of between 250 cP and 400 cP.
In some cases, the pharmaceutical formulation may be characterized by an osmolality of about 200 milliosmol (mOsm) / kg or more, about 220 mOsm / kg or more, about 240 mOsm / kg or more, about 260 mOsm / kg or more, about 280 mOsm / kg or more, or about 300 mOsm / kg or more.
In some instances, the lyophilized formulation further comprises an alpha-2 adrenergic receptor agonist, preferably wherein the alpha-2 adrenergic receptor agonist is clonidine or a derivative thereof.
In particular, the lyophilized pharmaceutical formulation further comprises an alpha-2 adrenergic receptor agonist, preferably in which the alpha-2 adrenergic receptor agonist is selected from the group consisting of clonidine and its derivatives.
The term "alpha-2 adrenergic receptor agonist", "alpha-2-adrenergic receptor agonist" or "0-2 adrenergic receptor agonist" refers to agents which mediate the inhibition of adenylyl activity. cyclase.
Alpha-2 adrenergic receptor agonists are at least partially selective for the alpha-2 adrenergic receptor. In some cases, the alpha-2 adrenergic receptor may not be the sole target of the agent. In other cases, the pharmaceutical formulation contains more than one alpha-2 adrenergic receptor agonist. In still other cases, the different alpha-2 adrenergic receptor agonists have a synergistic effect. In still other instances, the alpha-2 adrenergic receptor agonist is a synthetic compound having increased affinity for the alpha-2 adrenergic receptor over any natural alpha-2 adrenergic receptor ligand. In some versions, the alpha-2 adrenergic receptor agonist engages in a covalent interaction with the alpha-adrenergic receptor.
2. In yet other cases, the alpha-2 adrenergic receptor agonist does not physically interact with the alpha-2 adrenergic receptor and / or functions by interacting with natural ligands of the alpha-2 adrenergic receptor and / or by influencing their level of cellular expression. Alpha-2 adrenergic receptor agonists reduce pain through analgesic and anti-inflammatory effects. The term "analgesic" as defined herein refers to analgesic, pain relieving or pain relieving properties. Analgesic components or compounds are used to achieve analgesia, pain relief.
In certain cases, the alpha-2 adrenergic receptor agonist can be chosen from the group consisting of clonidine and its derivatives, in particular 2,6-dimethylclonidine, 4-azidoclonidine, 4-carboxyclonidine-methyl 3,5- dichlorotyrosine, 4-hydroxyclonidine, 4-iodoclonidine, alinidine, apraclonidine, chlorethylclonidme, clonidine 4-isothiocyanate, clonidine 4-methylisothiocyanate, clonidine receptor, clonidine displacing substance, hydroxyphenacetyl aminoclonidin, -dimonethylidin, -dimonethylidin, N-dimonethyl-n, aminoclonidine and tiamenidine; imidazolidines, including imidazolines, impromidine, detomidine, medetomidine, dexmedetomidine, levamisole, losartane, lofexidme, miconazole, naphazoline, niridazole, nitroimidazoles, ondansetron, oxymetazoline, phentolamine, tetramazole, tetramazoline, tetramazidine, tetramazidine, imidazoles, including 4- (3-butoxy-4-methoxybenzyl) imidazolidin-2-one, urocanic acid, amino-imidazole carboxamide, antazoline, biotin, bis (4-methyl-1-homo piperazinylthiocarbonyl) disulfide, carbimazole, cimetidine, clotrimazole, creatinine, dacarbazine, dexmedetomidine, econazole, enoximone, ethymizol, etomidate, fadrozole, fluspirilene, idazoxan, mivazerol; guanidines, including agmatme, betanidine, biguanides, cimetidine, creatme, gabexate, guanethidine, guanethidine sulfate, guanclofine, guanfacine, guanidine, guanoxabenz, impromidine, i0do-3 benzylguanidine, methylguanidine, mitoguaguanidin, nitrosoganidine, mitoguaguanidin, nitrosoganidine, mitoguaguanidin, nitrosoganidine, mitoguaguanidin, nitrosoganidine, mitoguaguanidin, nitrosoganidine, mitoguaguanidin, nitrosoganidine, mitoguaguanidin, nitrosoganidine, mitoguaguanidin, nitrosoganidine, mitoguaguanidine, nitrosoganidine, alpha-methylinorephrine, azepexole, 5-bromo-6- (2 imidazolidine-2-vlamino) quinoxaline, formoterol fumarate, indoramine, 6-allyl-2-amino-5,6,7,8-tetrahydro4H-thiazolo [4, 5-Djazepine diHCl, nicergoline, rilmenidine and xylazine.
In some cases, the lyophilized pharmaceutical formulation may contain clonidine. In some instances, the lyophilized pharmaceutical formulation comprises clonidme and at least one clonidine derivative. In other cases, the clonidine may be added to the formulation or be present in the formulation as the clonidine HCl.
In yet other cases, clonidine is present in the formulation in the form of one or more of the non-limiting groups that compose it: Arkamin, Aruclonin, Atensina, Catapin, Catapres, Catapresan, Catapressan, Chianda, Chlofazolme, Chlophazolin, Clonid-Ophthal, Clonidin, Clonidina, Clonidinä, Clonidine, Clonidine hydrochloride, Clonidine hydrochloride, Clonidini, Clonidmum, Clonigen, Clonistada, Clonnint, Clophelinum, Dixant, Duraclon, Edolglau, Haemiton, Isconoglodin, Jenporo Kapvay, Klofelino, Kochaniin, Melzin, Menograine, Normopresan, Paracefan, Pinsanidine, Run Rui and Winpress.
In some cases, the lyophilized pharmaceutical formulation corresponding to an administration dose may comprise from 1 µg to 500 µg of the alpha-2-adrenergic receptor agonist, or from 25 to 400 µg, or from 50 to 250 µg, of the alpha-2-adrenergic receptor agonist. alpha-2-adrenergic receptor agonist. In some cases, the lyophilized formulation may comprise from 50 µg to 150 µg, for example about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, about 110 µg or about 120 µg of the agonist. alpha-2-adrenergic receptor. Preferably, the formulation corresponding to an administration dose comprises from 2 µg to 250 µg of the alpha-2-adrenergic receptor agonist, more preferably from 5 µg to 125 µg of the alpha-2-adrenergic receptor agonist. .
In certain cases, the formulation corresponding to an administration dose may comprise: - from 1 mg to 100 mg of hyaluronic acid or its derivative, preferably from 2 mg to 50 mg of hyaluronic acid or its derivative, more preferably from 5 mg to 40 mg of hyaluronic acid or its derivative; and - optionally from 1 µg to 500 µg of the alpha-2-adrenergic receptor agonist, preferably from 2 µg to 250 µg of the alpha-2-adrenergic receptor agonist, more preferably from 5 µg to 125 µg of alpha-2-adrenergic receptor agonist.
In some cases, the lyophilized pharmaceutical formulation may comprise between 0.01% and 0.1% by weight of an alpha-2-adrenergic receptor agonist, such as clonidine or a derivative thereof. For example, the lyophilized pharmaceutical formulation may comprise from about 0.05% to about 0.1% by weight of an alpha-2-adrenergic receptor agonist, such as clonidine or a derivative thereof.
In some cases, the lyophilized pharmaceutical formulation further comprises at least one salt. In some cases, the salt is a calcium salt. In some forms of presentation, the salt may be (di) calcrum chloride (CaCl;).
Ca ™ can be added to current pharmaceutical compositions, for example to improve their coagulation and / or gelation in situ (eg, when the concentration of Ca ™ found at the site of administration is judged or should be insufficient to facilitate coagulation / gelation of the compositions alone), or to achieve a certain degree of coagulation / gelation in vitro before or after administration (eg, to improve injection capacity and / or product integrity). In these cases, the Ca ”can be added to the pharmaceutical composition at a concentration of between about 0.1 and 5% by weight, preferably between about 0.5 and 3% by weight, and more preferably between about 0.5. and 2% by weight (in the form of calcium relative to the total weight of the formulation).
Ca ”can be suitably included in pharmaceutical compositions by adding thereto an appropriate amount of pharmaceutically acceptable calcrum salt (s), preferably soluble calcium salt (s). . These Ca salts can be formed with inorganic or organic acids. Among the examples of such salts, mention may be made of calcium (di) chloride (CaCb), calcium glycerophosphate, calcium phosphate, calcium hydrogencarbonate, calcium citrate, calcium sulfate, calcium lactate. calcium, calcium gluconate, calcium ascorbate and mixtures thereof. CaCl is particularly preferred because it exhibits good solubility and is well tolerated in injectable solutions.
Pharmaceutical formulations corresponding to an administration dose referred to herein may comprise between about 1 mg and about 10 mg of CaCl, preferably between about 2 mg and 8 mg, preferably between about 3 mg and about 7 mg of CaCl. In some instances, products for intra-articular or peri-articular administration may contain between about 1 mg and about 10 mg of CaCl, preferably between about 2 mg and about 7 mg, preferably about 5 mg of CaCl ;. In some other instances, products intended for intraosseous or periosseous administration may contain between about 1 mg and about 10 mg of CaCl 3, preferably between about 2 mg and about 7 mg, preferably about 5 mg of CaCl 3. CaCl :.
In some cases, the lyophilized pharmaceutical formulation may contain between 1.5% and 3.0% by weight of salt, in particular a calcium salt such as calcium chloride. For example, the lyophilized pharmaceutical formulation can comprise between 2 and 3% by weight of the salt, in particular a calcium salt such as calcium chloride.
In some cases, the lyophilized pharmaceutical formulation further comprises at least one buffer solution comprising a weak acid and its conjugate base or vice versa (i.e. a weak base and its conjugate acid) to buffer the pH of the composition. .
In some instances, the lyophilized pharmaceutical formulation further comprises at least one buffering component, particularly a buffering component configured for safe use in pharmaceutical applications.
In some cases, the buffer can be an acidic buffer.
In other cases, the buffer can be a basic buffer.
In still other variations, the buffer can be a phosphate buffer, such as phosphate buffered saline (PBS). In some cases, the lyophilized pharmaceutical formulation may comprise between 0.1% and 2.0% by weight of the buffer component.
For example, the lyophilized pharmaceutical formulation can comprise between 0.5% and 1% by weight of the buffer component.
In some instances, the buffering component may be selected from the group of non-limiting examples comprising 4- (cyclohexylamino) -1-butanesulfonic acid (CABS), N-cyclohexyl-3-aminopropanesulfonic acid (CAPS), 2-amino-2-methyl-1-propanol (AMP), N-cyclohexyl-2-hydroxyl-3-amimopropanesulfonic acid (CAPSO), N-cyclohexyl-2-aminoethanesulfonic acid (CHES), N- (1,1) acid -dimethyl-2-hydroxyethyl) -3-amino-2-hydroxypropanesulfonic acid (AMPSO), N-tris (hydroxymethyl) methyl-4-aminobutanesulfonic acid (TABS), 2-amino-2-methyl-1,3-propanediol (AMPD) ), [tris (hydroxymethyl) methylamino] propanesulfonic acid (TAPS), N- @ -hydroxyethyl) piperazme-N '- (4-butanesulfonic acid) (HEPBS), 2- (Bis (2- - hydroxyethyl) amino) acetic acid (bicine), N- (2-hydroxy-1,1-bis (hydroxymethyl) ethyl) elycin (tricine), 3- [4- (2-hydroxyethyl) piperazin-1-yl] | propane-1-sulfonic acid ( EPPS), triethanolamine (TEA), acid = piperazine-1,4-bis (2-hydroxypropanesulfonic) dihydrate (POPSO), N- (hydroxyethyl acid ) piperazine-N'-2-hydroxypropanesulfonic (HEPPSO), tris (hydroxymethyl) aminomethane (trizma) acid, 3 - [[1,3-dihydroxy-2- (hydroxymethyl) propan-2-yllamino] -2-hydroxypropane- acid 1-sulfonic acid (TAPSO), 4- (N-morpholmo) butanesulfonic acid (MOBS), 3-bis (2-hydroxyethyl) amino-2-hydroxypropane-1-sulfonic acid (DIPSO), 4- (2-hydroxyethyl) acid -1-piperazineethanesulfonic acid (HEPES), 2 - [[1,3-dihydroxy-2- (hydroxymethyl) propan-2-yl | amino] ethanesulfonic acid (TES), 3- (N-morpholino) propanesulfonic acid (MOPS), 2- [bis (2-hydroxyethyl) amino] ethanesulfonic acid (BES), bis-trs propane (BTP), 3- (N-morpholino) hydroxypropanesulfonic acid (MOPSO), piperazine-N, N'-bis (2- acid ethanesulfonic) (PIPES), N- (2-acetamido) -2- aminoethanesulfonic acid (ACES), 2 - [(2-amino-2-oxoethyl) - (carboxymethyl) aminoJacetic acid (ADA), 2- [Bis (2 -hydroxyethyl) amino] -2- (hydroxymethyl) propane-1,3-diol (Bis-Tris), 2- (N-morpholino) ethanesulfonic acid (MES). The compositions of these buffer solutions and their preparation methods are described in the scientific literature and are therefore known to a person skilled in the art.
In some models, the buffer component is replaced by an acidic component such as hydrochloric acid (HCl). In some instances, the lyophilized pharmaceutical formulation further comprises at least one acidic component.
In some models, the acid component is hydrochloric acid (HCI). In some cases, the lyophilized pharmaceutical formulation may contain between 0.1% and 2.0% by weight of the acid component, such as HCl. For example, the lyophilized pharmaceutical formulation can comprise between 0.5% and 1% by weight of the acid component, such as HCl.
In the representations, the formulation may further comprise at least one salt, preferably a calcium salt, more preferably calcium chloride; and / or may further comprise at least one buffering component or one acid component, preferably hydrochloric acid. In some cases, the lyophilized pharmaceutical formulation comprises S / D plasma proteins and hyaluronic acid. In some instances, the lyophilized pharmaceutical formulation includes S / D plasma proteins, hyaluronic acid and clonidine or a derivative thereof. In some cases, the lyophilized pharmaceutical formulation comprises S / D plasma proteins, hyaluronic acid and optionally clonidine or a derivative thereof, calcium (di) chloride and / or hydrochloric acid.
In some cases, the lyophilized pharmaceutical formulation comprises S / D plasma proteins, hyaluronic acid, clonidine or a derivative thereof, calcium (di) chloride and hydrochloric acid.
In some cases, the lyophilized pharmaceutical formulation comprises about 30 to 80% by weight of plasma proteins or their derivatives, and about 5 to 20% by weight of hyaluronic acid or a derivative thereof. In some cases, the lyophilized pharmaceutical formulation comprises about 30 to 80% by weight of plasma proteins or their derivatives, about 5 to 20% by weight of hyaluronic acid or a derivative thereof and about 0.01 to. 0.1% by weight of an alpha-2-adrenergic receptor agonist.
In some cases, the lyophilized pharmaceutical formulation comprises about 30 to 80% by weight of plasma proteins or their derivatives, and about 5 to 20% by weight of hyaluronic acid or its derivative, and optionally about 0.01% to about 0, 1% by weight of the alpha-2-adrenergic receptor agonist; from about 1.5% to about 3.0% by weight of the salt; and / or from about 0.1% to about 2.0% by weight of the buffer component or the acid component. In some instances, the lyophilized pharmaceutical formulation comprises: from about 40% to about 75% by weight of plasma proteins or their derivatives; and from about 5.0% to about 20.0% by weight of the hyaluronic acid or its derivative; and optionally from about 0.01% to about 0.1% by weight of the alpha-2-adrenergic receptor agonist; from about 1.5% to about 3.0% by weight of the salt; and / or from about 0.1% to about 2.0% by weight of the buffer component or the acid component. In some cases, the lyophilized pharmaceutical formulation comprises from about 40% to about 75% by weight of the plasma proteins or their derivatives; and from about 10.0% to about 12.5% by weight of the hyaluronic acid or its derivative; and optionally from about 0.05% to about 0.1% by weight of the alpha-2-adrenergic receptor agonist; from about 2.0% to about 3.0% by weight of the salt; and / or from about 0.5% to about 1.0% by weight of the buffer component or the acid component.
In some cases, the lyophilized pharmaceutical formulation comprises from about 50% to about 70% by weight of the plasma proteins or their derivatives; and from about 10.0% to about 12.5% by weight of the hyaluronic acid or its derivative; and optionally from about 0.05% to about 0.1% by weight of the alpha-2-adrenergic receptor agonist; from about 2.0% to about 3.0% by weight of the salt; and / or from about 0.5% to about 1.0% by weight of the buffer component or the acid component.
In some cases, the lyophilized pharmaceutical formulation comprises from about 30% to about 80% by weight of the plasma proteins or their derivatives; about 5.0% to about 20.0% by weight of the hyaluronic acid or its derivative; about 0.01% to about 0.1% by weight of the alpha-2-adrenergic receptor agonist; about 1.5% to about 3.0% by weight of the salt; and about 0.1% to about 2.0% by weight of the buffer component or the acid component.
In particular, the lyophilized formulation according to the present invention comprises between 30% by weight and about 80% by weight of plasma proteins or their derivatives, between 5.0 and 20.0% by weight of hyaluronic acid or one of its derivatives. derivatives, and preferably between 0.01 and 0.1% by weight of an agonist of the alpha-2-adrenergic receptor as provided 1c1, preferably clonidine or a derivative of clonidine; and / or between 1.0 and 5.0% by weight of a salt, preferably a calcium salt, as provided herein, more preferably calcium chloride, with a percentage by weight based on the total weight of the Lyophilized formulation.
More particularly, the lyophilized formulation comprises between 30% by weight and 70% by weight of plasma proteins or their derivatives, between 5.0 and 15.0% by weight of hyaluronic acid or of a derivative thereof, and preferably between 0.05 and 0.1% by weight of an alpha-2-adrenergic receptor agonist as provided herein and / or between 1.5 and 3.0% by weight of a salt, preferably a calcium salt, as provided herein, with a percentage by weight based on the total weight of the lyophilized formulation.
In other instances, the lyophilized pharmaceutical formulation further comprises or may be co-administered with one or more other active pharmaceutical ingredients. "active pharmaceutical ingredient" or "API", as referred to here, should be interpreted according to the definition of the term given by the World Health Organization: a substance used in a finished pharmaceutical product (PFP), intended to exert an activity pharmacological or to have a direct effect on the diagnosis, cure, alleviation, treatment or prevention of a disease, or to have a direct effect on the restoration, correction or modification of physiological functions in the human being human.
In some cases, at least one active pharmaceutical ingredient is added to the formulation prior to lyophilization.
In this case, the release of each active principle can be identical or different, as for example in the case of a combination of two active principles where the first is presented in the form of immediate release and the second in the form of controlled release.
Likewise, a combination of immediate release form and controlled release form can also be obtained for the same active ingredient, in order to provide a quick and lasting effect.
In the other versions, at least one active pharmaceutical ingredient is added during reconstitution.
In still other cases, the additional active pharmaceutical formulation is added immediately prior to administration to the patient.
In some versions, the pharmaceutical formulation includes at least two additional active pharmaceutical ingredients.
In other cases, the various additional pharmaceutical active ingredients are added at different times during the manufacture of the pharmaceutical formulation.
In addition, the lyophilized pharmaceutical formulation comprises or can be co-administered with one or more other active pharmaceutical ingredients, in which the active pharmaceutical ingredient (s) are, each independently, selected from the group consisting of: a cellular composition, a principle pharmaceutical active agent, a protein, a peptide and a small organic molecule.
The applicability of the present invention is not limited to a pharmaceutical active ingredient or a class of pharmaceutical active ingredients.
The active pharmaceutical ingredient can be pharmacologically active itself, or can be converted to a pharmacologically active species by a chemical or enzymatic process in the body, i.e. the active pharmaceutical ingredient can be a prodrug.
Current pharmaceutical formulations can be particularly useful for unstable pharmaceutical active ingredients.
Among the non-limiting examples of unstable pharmaceutical active ingredients are peptides and proteins such as growth factors, peptide-type active ingredients, antibodies and vaccines, small interfering RNAs (siRNA), DNA, hormones, etc.
The term "growth factor" as used herein refers to a biologically active substance which influences the proliferation, growth, differentiation, survival and / or migration of various types of cells, and can affect the changes. developmental, morphological and functional of an organism, either alone or modulated by other substances.
A growth factor can generally act by binding, as a ligand, to a receptor (eg, a surface or intracellular receptor) present in cells sensitive to growth factor.
A growth factor can in particular be a protein entity comprising one or more polypeptide chains.
By way of example and without limitation, the term "growth factor" includes members of the family of fibroblast growth factors (FGF), of the family of bone morphogenetic proteins (BMP), of the family of growth factors platelet-derived (PDGF), transforming growth factor beta (TGFP) family, nerve growth factor (NGF) family, epidermal growth factor (EGF) family, growth factor family insulin-like (IGF), growth differentiation factor (GDF) family, hepatocyte growth factor (HGF) family, hematopoietic growth factors (HeGF), platelet-derived endothelial cell growth factor (PD-ECGF) ), angiopoietin, family of vascular endothelial growth factors (VEGF), glucocorticoids, etc.
The term "pharmaceutical active ingredient" also encompasses any pharmacologically active salt, ester, N-oxide or prodrug of the compound or substance in question.
In particular, the lyophilized pharmaceutical formulation can further comprise one or more substances having osteogenic or chondrogenic, osteo or chondro-inductive and / or osteo or chondro-conductive properties.
In preferred forms of presentation, this substance may be selected from the group comprising or consisting of fibroblast growth factor (FGF), preferably FGF-2, transforming growth factor beta (TGFB), preferably TGFB-1 , a platelet-derived growth factor (PDGF), interleukin-8 (IL-8), a bone morphogenetic protein (BMP), for example one or more of BMP-2, BMP-4, BMP-6 and BMP -7, parathyroid hormone (PTH), parathyroid hormone bound protein (PTHrp), VEGF and stem cell factor (SCF). Each of these substances can be included in a pharmaceutical composition at a concentration sufficient to achieve the desired osteogenic, osteoinductive and / or osteoconductive effect (s) when administered to a subject, while avoiding where possible unwanted side effects.
As a rule, but without limitation, such a substance can be included in the pharmaceutical formulation at a concentration of from 0.01 ng / mg to 1 mg / mg, for example 0.1 ng / mg - to 100 µg / mg, for example 1 ng / mg to 50 µg / mg.
The term "osteo-inductive" refers to the ability of a component such as a peptide growth factor to recruit immature cells such as stem cells, MSCs and to stimulate these cells to differentiate pre-. osteoblasts and mature osteoblasts, thereby forming bone tissue.
The present pharmaceutical compositions may further comprise a component having osteoinductive properties such as an osteoinductive protein or peptide, for example a bone morphogenetic protein, such as BMP-2, BMP-7 or BMP-. 4; a hydrogel or a biopolymer such as hyaluronic acid or its derivatives, collagen, fibrinogen, osteonectin or osteocalcin.
Preferably, the pharmaceutical compositions can also comprise hyaluronic acid or derivatives thereof, collagen or fibrinogen.
The term "osteoconductive" refers to the ability of a component to act as a support on which bone cells can attach, migrate, grow and produce new bone. The pharmaceutical compositions may further comprise a component having osteoconductive properties, for example, an osteoconductive matrix or surface such as, without limitation, tricalcium phosphate, hydroxyapatite, the combination of hydroxyapatite / phosphate particles. tricalcium (HA / TCP), gelatin, poly-lactic acid, glycolic poly-lactic acid, hyaluronic acid, chitosan, poly-L-lysine or collagen.
Pharmaceutical formulations according to the present invention may further include or be co-administered with a complementary bioactive factor or an osteoinductive protein such as a bone morphogenetic protein, such as BMP-2, BMP-7 or BMP-4, or any other growth factor. Other potential accompanying ingredients include inorganic sources of calcium or phosphate which may promote bone regeneration (WO 00/07639). If desired, the cell preparation can be administered on a matrix or a support material to enhance tissue regeneration. For example, the material can be a hydrogel or a biopolymer such as gelatin, collagen, hyaluronic acid or its derivatives, osteonectin, fibrmogen or osteocalcin. Biomaterials can be synthesized according to standard techniques (eg, Mikos et al., Biomaterials 14: 323, 1993; Mikos et al, Polymer 35: 1068, 1994; Cook et al, J. Biomed. Mater. Res. 35: 513, 1997).
Generally, the lyophilized pharmaceutical formulation is mixed with at least one aqueous solution prior to administration, preferably wherein the aqueous solution is water for injection.
The terms "water for injection", "aqua ad injectabilia", "aqua ad injectionem", "WFI" or "aqua ad ini", as defined in this document, refer to water without significant contamination capable of being injected. to a person. As defined herein, water is considered sterile and / or other substances are added to make the solution approximately isotonic. In some cases, the aqueous solution may be physiological saline or saline solution. isotonic.
Saline solution is a mixture of sodium chloride in water and has many uses in medicine known to a specialist. A common saline solution contains about 9 grams of sterile salt per liter of solution. In some cases, the amount of salt per liter may be different.
In some cases, additional active pharmaceutical ingredients are added to the aqueous solution before being mixed with the ivophilized pharmaceutical formulation. In other cases, the aqueous solution contains at least one pharmaceutical excipient. In other cases, the aqueous solution may have a temperature of about 10 ° C to about 37 ° C.
In some cases, the aqueous solution used to reconstitute the lyophilized pharmaceutical formulation may include biological material.
By way of indication and without limitation, this biological material can be a cellular composition which can comprise mesenchymal stem cells (MSCs), osteoprogenitors, osteoblast cells, osteocytes, chondroblast cells and / or chondrocytes.
The pharmaceutical formulation therefore makes it possible to deliver such a cellular composition.
This viscous quality of current pharmaceutical formulations can ensure localized delivery and an appropriate supporting environment for the delivered cells.
The term "mesenchymal stem cell" or "MSC" as used herein refers to an adult stem cell derived from the mesoderm capable of generating cells of mesenchymal lineages, generally of two or more mesenchymal lineages, e.g., osteocytic. (bone), chondrocyte (cartilage), myocytic (muscle), tendonocytic (tendon), fibroblast (connective tissue), adipocyte (fat) and stromogen (stroma of the marrow). MSC can be isolated from, for example, bone marrow, trabecular bone, blood, umbilical cord, placenta, fetal yolk sac, skin (dermis), especially fetal skin and adolescent, periosteum and adipose tissue.
Human MSCs, their isolation, in vitro expansion and differentiation have been described in, for example, US Pat. No. 5,486,359; US Pat.
No. 5,811,094; US Pat.
No. 5,736,396; US Pat.
No. 5,837,539; or US Pat.
No. 5,827,740. Any MSC described in the present study and isolated by a method described in the present study may be suitable in current pharmaceutical formulations.
The term MSC also encompasses the descendants of MSC, for example the descendants obtained by proliferation (propagation) in vitro or ex vivo of MSC obtained from a biological sample of an animal or a human subject.
MSCs preferably have the potential to generate cells of at least the osteogenic (bone) lineage, such as, for example, osteoprogenitors and / or pre-osteoblasts and / or osteoblasts and / or osteocytes, etc. or at least the chondrogenic line (cartilage), such as, for example, chondrogenic cells and / or chondroblasts and / or chondrocytes, etc.
The term "stem cell" generally designates an unspecialized or relatively less specialized cell capable of proliferation, which is capable of self-renewal, that is to say which can proliferate without differentiating, and which or whose offspring can give rise to at least one relatively more specialized cell type.
The term embraces stem cells capable of substantially unlimited self-renewal, i.e., the offspring of a stem cell or at least a portion thereof retain substantially the unspecialized or relatively less specialized phenotype. , the differentiation potential and proliferative capacity of the parent stem cell, as well as stem cells which exhibit limited self-renewal, that is, the capacity of the offspring or part of it. ci to continue its proliferation and / or its differentiation is clearly reduced compared to the parent cell. By way of example and not of limitation, a stem cell can give rise to descendants which can differentiate according to one or more lines to produce more and more specialized cells, these descendants and / or more and more specialized cells which may themselves be stem cells as defined herein, or even to produce terminally differentiated cells, i.e. fully specialized cells, which may be post-mitotic.
The term "adult stem cell" as used 1c1 refers to a stem cell present in or obtained from an organism (such as isolated) at the fetal stage or after birth, such as after reaching adulthood.
In the present document, "osteoprogenitors" can include in particular early and late osteoprogenitors. The “osteoblast cells” can in particular comprise the pre-osteoblasts, the osteoblasts and the osteocytes, and the term can preferentially designate the pre-osteoblasts and the osteoblasts. All of these terms are well known per se and, as used herein, can generally refer to cells having an osteogenic phenotype and which may contribute to the formation of bone material or bone matrix, or which are capable of develop into cells that can contribute to this formation.
Through other orientations and not limitations, osteoprogenitors and osteoblast cells, as well as cell populations comprising osteoprogenitors and / or osteoblast cells may exhibit the following characteristics: a) cells comprise expression of Runx2, a multifunctional transcription factor which regulates osteoblast differentiation and expression of numerous extracellular matrix protein genes during osteoblast differentiation; b) the cells comprise the expression of at least one of the following elements: alkaline phosphatase (ALP), more precisely ALP of the bone-liver-kidney type; and preferably also include the expression of one or more additional bone markers such as osteocalcin (OCN), type 1 procollagen, amino-terminal propeptide (PINP), osteonectin (ON), l osteopontin (OP) and / or bone sialoprotein (BSP), and / or one or more additional bone matrix proteins such as decorin and / or osteoprotegerin (OPG); ©) cells express virtually no CD45 (e.g. less than about 10%, preferably less than about 5%, preferably less than about 2% of cells can express CD45): d) cells show signs ability to mineralize the external environment or to synthesize an extracellular matrix containing calcium (for example, when exposed to an osteogenic medium; see Jaiswal et al.
J Cell Biochem, 1997, vol. 64, 295-312). Calcium build-up inside cells and its deposition in matrix proteins can be measured in a conventional manner, for example by growing in `` Ca '', washing and recultivating, then determining any radioactivity. present inside the cell or deposited in the extracellular matrix (US 5,972,703), or using an alizarin red mineralization test (see, e.g., Gregory et al.
Analytical Biochemistry, 2004, vol. 329, 77-84); e) the cells do not substantially differentiate to any of the adipocyte (eg, adipocytes) or chondrocyte (eg, chondrocytes) lineage cells. The absence of differentiation to such cell lines can be tested using standard conditions for inducing differentiation established in the art (eg, see Pittenger et al.
Science, 1999, vol. 284, 143-7), and testing methods (e.g., when induced, fat cells usually stain petroleum red O showing accumulation of lipids; chondrocytes usually stain alcian blue or safranin O) . A substantial lack of propensity for adipogenic and / or chondrogenic differentiation may mean that less than 20%, or less than 10%, or less than 5%, or less than 1% of the cells tested would show signs of adipogenic or chondrogenic differentiation when 'they are applied to the respective test.
The cells can further comprise the expression of one or more cellular recruitment factors such as IL6 and / or VEGF.
In the present document, the “chondroblast cells” can in particular comprise chondroblasts, that is to say young cartilage cells (non-mature, immature) active in the secretion of the extracellular matrix.
Chondroblasts are considered to arise by differentiation from mesenchymal stem cells.
The term “chondrocyte” more precisely designates a mature cartilage cell necessary for maintaining the cartilage matrix.
These terms are well known per se and, as used herein, may - generally refer to cells having a chondrogenic phenotype and which may contribute to the formation of cartilage or cartilage matrix, or are capable of develop into cells that can contribute to this formation.
When a cell is said to be positive for a particular marker (or expresses or understands the expression of this marker), this means that a person skilled in the art will conclude in the presence or in the proof of a distinct signal, for example an antibody detectable or reverse transcription polymerase chain reaction detection, for this label when taking the appropriate measurement, against appropriate controls.
When the method allows quantitative evaluation of the marker, positive cells can on average generate a signal that is significantly different from that of the control, for example, but without limitation, at least 1.5 times higher than that signal generated by the cells. controls, for example, at least 2 times, at least 4 times, at least 10 times, at least 20 times, at least 30 times, at least 40 times, at least 50 times higher or even higher.
Expression of the above specific cell markers can be detected by any suitable immunological technique known in the art, such as immunocytochemistry or affinity adsorption, Western blot analysis, FACS, ELISA, etc., or by any appropriate biochemical test of the enzymatic activity (for example for ALP), or by any suitable technique for measuring the quantity of the mRNA of the marker, for example Northern blot, semi-quantitative or quantitative RT-PCR, etc.
Sequence data for the markers listed in this disclosure are known and can be obtained from public databases such as GenBank (http: //Www.ncbi.nlm nih.gov/). The cells of the cellular composition may be animal cells, preferably warm blooded animal cells, more preferably mammalian cells, such as human cells or non-human mammalian cells, and more preferably human cells.
In some cases, the pharmaceutical formulation is supplied in a kit of parts.
The kit of parts can comprise the lyophilized pharmaceutical formulation as defined in any embodiment of the present invention, contained in one or more storage containers or vials, in particular with each vial corresponding to a treatment dose, a syringe comprising an aqueous solution.
Preferably, the kit of parts further comprises at least one needle.
The kit of parts may contain the pharmaceutical formulation as defined in any form of incorporation described in the present invention.
In some versions, the amount of syringes and / or needles can be adjusted depending on the amount of lyophilized pharmaceutical formulation contained in the storage vial.
In some versions, the kit may additionally contain a disinfectant and / or an anti-inflammatory.
The anti-inflammatory component can be selected from a group comprising a treatment liquid, a spray, a lotion, a cream, an ointment, a gel, a gum, a plaster, a skin patch, a plaster.
The anti-inflammatory components have been described in the state of the art.
In other versions, the kit may include instructions for reconstituting the lyophilized formulation and / or instructions for administration.
In another version, the lyophilized formulation is contained in a dual chamber syringe and is fully reconstituted in the syringe.
In another embodiment, the lyophilized formulation is contained in a multi-chamber syringe, such as a dual syringe comprising the freeze-dried pharmaceutical composition in one compartment and the aqueous solution in a second compartment.
In another version, the parts kit may include more than one vial.
In some form, the kit comprises vials with different ivophilized pharmaceutical formulations, in which hyaluronic acid or a derivative thereof and / or plasma proteins or derivatives thereof vary between different formulations.
In other versions, the vials differ in that the lyophilized pharmaceutical formulation comprises different alpha-2 adrenergic receptor agonists and / or a salt and / or a buffer or an acid component.
In some versions, the kit includes an additional component that allows the degree of reconstitution to be tested.
In still other cases, the kit comprises at least one bandage, a skin patch or a plaster cast.
Another aspect relates to a process for preparing a lyophilized pharmaceutical formulation as taught herein, comprising the following steps: a) admixing plasma proteins or their derivatives, hyaluronic acid or a derivative thereof. ci and an aqueous solution, which makes it possible to obtain a bulk mixture having a concentration of plasma proteins or their derivatives of 20 mg / ml to 50 mg / ml and a concentration of hyaluronic acid or its derivative of 4 mg / ml to 8 mg / ml; b) sterilizing the bulk mixture by steam sterilization or filtration, thereby obtaining a sterile mixture; and (©) lyophilization of the sterile mixture, which makes it possible to obtain the lyophilized pharmaceutical formulation.
Preferably, one aspect provides a process for preparing a lyophilized pharmaceutical formulation as defined herein, comprising the following steps: (a) admixing plasma, such as S / D plasma, and hyaluronic acid or a derivative thereof, thereby obtaining a bulk mixture having a plasma protein concentration of 20 mg / ml to 50 mg / ml and a concentration of hyaluronic acid or a derivative thereof of 4 mg / ml to 8 mg / ml; (b) sterilization of the bulk mixture by steam sterilization or filtration, resulting in a sterile mixture (c) lyophilization of the sterile mixture, thereby obtaining the lyophilized pharmaceutical formulation.
In another aspect, the invention provides a process or method for preparing a lyophilized pharmaceutical formulation, comprising the following steps a) admixing the plasma proteins or their derivatives, preferably plasma proteins S / D, of hyaluronic acid or a derivative thereof and an aqueous solution, resulting in a bulk mixture; b) sterilization of the bulk mixture, thereby obtaining a sterile mixture; and
(c) lyophilization of the sterile mixture, thereby obtaining the lyophilized pharmaceutical formulation.
Accordingly, one aspect provides a process for preparing a lyophilized pharmaceutical formulation, comprising the following steps: (a) admixing plasma, preferably S / D plasma, and hyaluronic acid or a derivative thereof. , which makes it possible to obtain a bulk mixture; b) sterilization of the bulk mixture, thereby obtaining a sterile mixture; and (c) lyophilization of the sterile mixture, thereby obtaining the pharmaceutical formulation lyophilisce.
Further, one aspect provides a process for preparing a lyophilized pharmaceutical formulation, comprising the following steps: (a) admixing plasma, preferably S / D plasma, and hyaluronic acid or a derivative thereof. , which makes it possible to obtain a bulk mixture; b) sterilization of the bulk mixture, thereby obtaining a sterile mixture; and (c) lyophilization of the sterile mixture, thereby obtaining the lyophilized pharmaceutical formulation; wherein step (a) comprises the steps of (a1) dissolving hyaluronic acid or its derivative in an aqueous solution, thereby obtaining a first solution; (a2) preparing a second solution comprising the plasma and, optionally, an alpha-2 adrenergic receptor agonist, and (a3) mixing the first and the second solution to obtain the bulk mixture.
In the incorporated products, the bulk mixture has a plasma protein concentration of 20 mg / ml to 50 mg / ml and a concentration of hyaluronic acid or a derivative thereof of 4 mg / ml to 8 mg / ml.
The mixture of hyaluronic acid or its derivative is generally obtained by stirring, shaking, - decanting, turning, inverting, stirring or turning the hyaluronic acid and / or its derivative with the aqueous solution.
The first solution may comprise about 1.0 to 30 mg / ml of hyaluronic acid or a derivative thereof, preferably about 2.0 to 20 mg / ml, more preferably about 4.0 to 16.0 mg / ml of hyaluronic acid or a derivative thereof, for example about 8.0 to 12.0 mg / ml of hyaluronic acid or a derivative thereof.
The bulk mixture especially comprises about 1.0 to 15 mg / ml of hyaluronic acid or a derivative thereof, preferably about 2.0 to 10 mg / ml, more preferably about 4.0 to 8, 0 mg / ml of hyaluronic acid or a derivative thereof.
In some embodiments, plasma proteins, preferably S / D plasma proteins, are provided as S / D plasma.
Preferably the bulk mixture comprises about 70% to about 99.9% by weight S / D plasma in the pharmaceutical formulation, preferably about 75% to about 99%, or more preferably about 80% to about 97% by weight. S / D plasma weight.
Preferably, the second solution comprises from about 70% to about 100% by weight of plasma proteins, such as S / D plasma proteins, preferably from about 75% to about 99%, or more preferably from about 80 % to about 97% by weight of plasma proteins, such as S / D plasma proteins.
The bulk mixture comprises in particular between 20 mg / ml and 50 mg / ml of plasma proteins or of plasma protein derivatives.
In embodiments, the second solution can include between about 20% (v / v) and about 100% (v / v) plasma, such as S / D plasma.
For example, the second solution can include between 40% (v / v) and 99% (v / v), between 50% (v / v) and 98% (v / v), between 60% (v / v) and 97% (v / v), between 70% (v / v) and 96% (v / v), or between 80% (v / v) and 95% (v / v) of plasma, such as Sm plasma .
In the embodiments, the bulk mixture can comprise at most 50% (v / v) plasma such as S / D plasma.
In the incorporated products, the bulk mixture may comprise between about 10% (v / v) and about 50% (v / v) plasma, such as S / D plasma.
For example, the bulk mixture may include 20% (v / v) to 49% (v / v), 25% (v / v) to 48% (v / v), 30% (vv) to 47% (v / v), 35% (v / v) to 46% (v / v), or 40% (v / v) to 45% (v / v) of plasma, such as plasma S / D.
In some cases, the bulk mixture further comprises one or more of the following - an alpha-2-adrenergic receptor agonist as described herein, preferably clonidine or a derivative thereof: - a salt, preferably a calcium salt, such as calcium dichloride; and / or - a buffer component or an acid component, preferably HCl.
Accordingly, in some embodiments, step (a) further comprises the step of mixing an alpha-2 adrenergic receptor agonist, preferably clonidine, and / or a salt, preferably a calcium salt. , and / or a buffering component or an acid component, preferably HCl, thereby obtaining a bulk mixture in which the concentration of the alpha-2 adrenergic receptor agonist, preferably clonidine or a clonidine derivative such as 'contemplated herein is between 20 µg / ml and 35 µg / ml and / or wherein the concentration of the salt, preferably a calcium salt, more preferably calcium dichloride, is between 0.5 mg / ml and 1, 5 mg / ml.
In some cases, step (a) may further comprise admixing an alpha-2 adrenergic receptor agonist, a salt and / or a buffering component or an acid component, thereby allowing '' obtain a bulk mixture having an alpha-2 adrenergic receptor agonist concentration of 20 µg / ml to 35 µg / ml, a salt concentration of 0.5 mg / ml to 1.5 mg / ml and / or a concentration of the buffer component or the acid component of 0.05 mg / ml to 3.0 mg / ml.
In some cases, the bulk mixture further comprises one or more other components, including pharmaceutical excipients, serum and / or other blood components, other active pharmaceutical ingredients selected from a group consisting of an active pharmaceutical compound, a protein, a peptide and a small organic molecule.
In some embodiments, step (a) comprises the steps of (a1) dissolving hyaluronic acid or its derivative in an aqueous solution, thereby obtaining a first solution; (a2) preparing a second solution comprising the plasma proteins, and (a3) mixing the first and the second solution to obtain the bulk mixture.
In certain embodiments, step (a) comprises the following steps: (al) dissolving the hyaluronic acid or its derivative in an aqueous solution, which makes it possible to obtain a first solution; (a2) preparing a second solution comprising the plasma proteins and an alpha-2 adrenergic receptor agonist, and (a3) mixing the first and the second solution to obtain the bulk mixture.
In some embodiments, step (a) comprises the steps of (a1) dissolving hyaluronic acid or its derivative in an aqueous solution, thereby obtaining a first solution; (a2) preparing a second solution comprising the plasma and / or serum, and (a3) mixing the first and the second solution to obtain the bulk mixture.
In some embodiments, step (a) comprises the steps of (a1) dissolving hyaluronic acid or its derivative in an aqueous solution, which makes it possible to obtain a first solution; (a2) preparing a second solution comprising the plasma and / or serum, and an alpha-2 adrenergic receptor agonist, and (a3) mixing the first and the second solution to obtain the bulk mixture.
In some embodiments, step (a) comprises the step of dissolving hyaluronic acid or its derivative in an aqueous solution, which makes it possible to obtain a first solution.
In some embodiments, the hyaluronic acid or its derivative is first dissolved in an aqueous solution, which makes it possible to obtain a first solution, before being mixed with a second solution.
The step of dissolving hyaluronic acid or its derivative in an aqueous solution can last at least 10 hours, such as at least 12 hours, at least 14 hours, at least 16 hours or at least 18 hours. This step allows the complete hydration of the hyaluronic acid or its derivative.
In some embodiments, step (a) includes the step of preparing a second solution comprising the plasma proteins. In some cases, step (a) comprises preparing a second solution comprising the plasma and / or serum. In some cases, the second solution further comprises additional components such as the non-limiting examples described above, in particular an alpha-2-adrenergic receptor agonist as described 1ci, preferably clonidine or a derivative thereof. , a salt and an acid component. Accordingly, in some embodiments, the method comprises (a2) preparing a second solution comprising the plasma proteins, an alpha-2-adrenergic receptor agonist as described herein, preferably clonidine or a derivative thereof. , a salt and an acid component. In some cases, the first solution comprising hyaluronic acid or a derivative thereof is mixed with the second solution comprising: plasma proteins, preferably S / D plasma; a 2-adrenergic receptor agonist as described herein, preferably clonidine or a derivative thereof; a salt; and an acidic component. In the embodiments, the method comprises (a2) preparing a second solution comprising plasma and / or serum, an alpha-2-adrenergic receptor agonist as described herein, preferably clonidine or a derivative of this, a salt and an acid component. In some cases, the first solution comprising hyaluronic acid or a derivative thereof is mixed with the second solution comprising: plasma and / or serum, preferably S / D plasma; a 2-adrenergic receptor agonist as described herein, preferably clonidine or a derivative thereof; a salt; and an acidic component. The salt can be, but is not limited to, a calcium salt such as calcium dichloride (CaCl2 or CaCl2.2H20). The acid component can be, but is not limited to, hydrogen chloride (HCl). It is understood that the first and the second solution described above are combined to obtain the bulk mixture.
In some embodiments, step (a) comprises the step of mixing the first and the second solution to obtain the bulk mixture. In some cases, the first solution and the second solution are mixed in a ratio of at least 1: 1 (v / v), for example in a ratio of 1.5: 1, 2: 1, 3: 1, 4 : 1 (v / v) or more. In some cases, the first solution and the second solution are mixed in a ratio of 1: 1 (v / v). Thus, the resulting lyophilized pharmaceutical formulation will have a satisfactory density, thus allowing rapid and homogeneous reconstitution of the lyophilized pharmaceutical formulation.
The term "mixing the first solution and the second solution in a 1: 1 (v / v) ratio" refers to mixing equal volumes of the first solution and the second solution. It is advantageous to mix equal volumes of the first and the second solution.
In some embodiments, the method of sterilization is filter sterilization. In the present document, the terms “sterilization by filter”, “sterilization by filtration” or “microporous filtration” designate a method having as its object the sterilization of a sample, of a mixture or of a formulation. In some embodiments, a membrane is used to achieve filtration, allowing the exclusion of components and / or organisms based on their size.
Other filtration methods are provided where the filter material used can include nylon, polycarbonate, cellulose, acetate, polyvinylidene fluoride (PVDF) and polyethersulfone (PES). These materials are characterized by differences in protein retention, flow rate and the presence of leachable materials.
In some incarnations, the method of sterilization is steam sterilization. In this case, the formulation is exposed to saturated steam at elevated temperatures, for example from about 121 ° C to about 134 ° C. By way of indication and without limitation, steam sterilization can be carried out using an autoclave. In some preparations, the steam sterilization temperature is between approximately 125 and 130 ° C. In some models, different sterilization methods can be combined. In other cases, the different sterilization methods are applied successively. In some models, the formulation is subjected to steam sterilization for approximately 3 to 30 minutes. In some cases, the formulation is subjected to steam sterilization for about 10 to 20 minutes.
The term "autoclave" as used herein refers to a pressure chamber capable of reaching high temperatures and pressures other than atmospheric pressure. The sterilization times required to achieve sterilization can vary depending on multiple parameters such as the amount and nature of the material to be sterilized. One skilled in the art knows that steam sterilization times can be inversely correlated with the steam sterilization temperature used.
By further guidance and without limitation, lyophilization can be performed in the following steps: filling individual sterile containers with aliquots of the bulk solution and partially capping the containers under aseptic conditions, transporting partially capped containers to the freeze dryer and loading into the chamber under aseptic conditions, freezing the solution by placing the partially stoppered containers on cooled shelves in one freeze-drying chamber or pre-freezing in another chamber, applying a vacuum to the chamber and heating the shelves in order to evaporate the water from the frozen state, and finally the complete sealing of the vials by hydraulic or threaded rod stopper mechanisms which can be installed in the freeze-drying device. In some models, no partial plugging is done on the samples at the start of the lyophilization process and full plugging is done after lyophilization.
"I BE2020 / 5332 The term" stopper "refers to the seal on a vial preventing the lyophilized formulation from escaping from the vial and / or allowing a sterile environment inside the vial to be contained. terms may be stoppers, lids, seals, crimp seals or any other means to close the vial.
The lyophilization step is possible using a variety of parameters, repeats thereof, in combination or in additional steps. The temperature and / or duration of the single or multiple freezing steps of the lyophilization process can be adjusted to achieve a specific size of ice crystals prior to sublimation. The drying phases are carried out under reduced pressures which can range from approximately 0.1 mbar to 0.005 mbar or from approximately 0.1 mbar to approximately 0.01 mbar. In other cases, the bulk mixture is aliquoted prior to lyophilization, so that the resulting vials contain an amount of the formulation corresponding to a single dose for administration. In other cases, aliquoting is performed after lyophilization. In the other variants, no aliquoting takes place and the resulting vial containing the pharmaceutical formulation corresponds to several administration doses. In still other cases, the resulting vial contains a volume greater than a volume corresponding to a natural number of administration doses in order to anticipate the adhesive effects of the reconstituted formulation on the walls of the vial, the sermgue or the stopper. . In other cases, this additional volume may be about 20% of the volume needed for a natural number of administration doses, about 15% of the volume needed, about 10% of the volume needed, about 5% of the volume needed, about 2 % of volume needed, about 1% of volume needed. In some instances, the lyophilized pharmaceutical formulation can be obtained or obtained by a method as defined herein. Another aspect relates to lyophilized pharmaceutical formulations obtainable or obtainable by any embodiment of the methods described herein. In some cases, the lyophilized pharmaceutical formulation comprises hyaluronic acid or a derivative thereof, plasma proteins and an alpha-2 adrenergic receptor agonist. In other incamations, the lyophilized pharmaceutical formulation consists of or consists primarily of hyaluronic acid, plasma proteins, clonidine, calcium chloride and a buffering component or an acidic component such as chloride. hydrogen. In particularly preferred embodiments, the pharmaceutical formulation comprises between about 30% by weight and about 80% by weight of plasma proteins, comprises between 5.0 and 20.0% by weight of hyaluronic acid fibers or a derived therefrom with a molecular weight of from about 0.2 MDa to 4.5 MDa, in particular from about 0.5 MDa to about 1.2 MDa, has a density of from about 0.04 to 0.08 mg / ml, and has a degree of swelling of from about 9 to about 30, and further comprising between 0.01 and 0.1% by weight of clonidine or a clonidine derivative, and / or between 1.5 and 3.0% by weight of a calcium salt, in particular calcium chloride.
A related aspect relates to the lyophilized pharmaceutical formulation as described above for use as a medicament.
A related aspect relates to the lyophilized pharmaceutical formulation as described above for use in the treatment (including, throughout this specification, therapeutic and / or preventive measures) of musculoskeletal disease. Preferably, said musculoskeletal disease may be bone disease or joint disease.
A "joint", "articular surface" or "joint", as defined in 1c1, refers to a connection between the bones of a body which connects the skeletal system into a functional whole. Joints suitable for treatment using the formulation Pharmaceuticals can be selected from the group consisting of monoarticular joints, oligoarticular or pauciarticular joints and polyarticular joints. Joints as defined herein may refer to one or more members of the functional classification group comprising fibrous joints, cartilaginous joints, synovial joints or facet joints. The joints can be selected from the group consisting of hand joints, elbow joints, wrist joints, axillary joints, sternoclavicular joints, vertebral joints, art temporomandibular joints, sacroiliac joints, hip joints, knee joints or joints of the foot.
Another aspect provides a method of treating a musculoskeletal disease in a subject in need of such treatment, comprising administering a therapeutically effective amount of a lyophilized pharmaceutical formulation as taught herein to the subject, in wherein the lyophilized pharmaceutical formulation is mixed with an aqueous solution prior to administration. Another aspect provides for the use of an ivophilized pharmaceutical formulation as taught herein for the manufacture of a medicament for the treatment of musculoskeletal disease in a subject.
The term "musculoskeletal disease" as used herein refers to any type of disease of the bone, muscle, joint or chondrodystrophy, the treatment of which may benefit from administration of the present pharmaceutical formulation to a subject afflicted with the disease. disease. The term also encompasses diseases affecting the tendons and / or ligaments). These diseases can in particular be characterized, for example, by a decrease in the formation of bone and / or cartilage or excessive resorption of bone and / or cartilage, by a decrease in the number, viability or function of osteoblasts or osteocytes present in bone and / or chondroblast or chondrocytes present in cartilage, decrease in bone mass and / or cartilage mass in a subject, thinning of bone, decrease in strength or the elasticity of the bone, etc.
Non-limiting examples of musculoskeletal diseases can include local or systemic disorders, such as any type of osteoporosis or osteopenia, eg, primary, postmenopausal, senile, induced by corticosteroids, bisphosphonates and radiotherapy; any secondary, mono- or multisite osteonecrosis; any type of fracture, for example, non-union, poorly-union fractures, delayed union or compression fractures, conditions requiring bone fusion (for example, spinal fusions and reconstructions), maxillofacial fractures, defects congenital bone, bone reconstruction, for example, after traumatic injury or cancer surgery, and craniofacial bone reconstruction; traumatic arthritis, focal cartilage and / or joint defect, focal degenerative arthritis; osteoarthritis, degenerative arthritis, knee osteoarthritis and coxarthrosis; osteogenesis imperfecta; osteolytic bone cancer; Paget's disease, endocrinological disorders, hypophosphatemia, hypocalcemia, renal osteodystrophy, osteomalacia, adynamic bone disease, hyperparathyroidism, primary hyperparathyroidism, secondary hyperparathyroidism; periodontal disease; Gorham-Stout disease and McCune-Albright syndrome; rheumatoid arthritis ; spondyloarthropathies, including ankylosing spondylitis, psoriatic arthritis, enteropathic arthropathy, and undifferentiated spondylitis and reactive arthritis; systemic lupus erythematosus and related syndromes; scleroderma and related disorders; Sjôgren's syndrome; systemic vasculants, including giant cell arteritis (Horton's disease), Takayasu's arteritis, polymyalgia rheumatica, vasculitis associated with ANCA (such as Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome ), Behcet syndrome and other polvarteritis and related disorders (such as polyarteritis nodosa, Cogan syndrome and Buerger's disease); arthritis accompanying other systemic inflammatory diseases, including amyloidosis and sarcoidosis; crystal arthropathies, especially gout, calcium pyrophosphate dihydrate disease, disorders or syndromes associated with joint deposition of calcium phosphate or calcium oxalate crystals; chondrocalcinosis and neuropathic arthropathy; Felty's syndrome and Reiter's syndrome; Lyme disease and rheumatic fever.
In embodiments, the musculoskeletal disease can be osteoarthritis. As used ict, a phrase such as "a subject in need of treatment" includes subjects who would benefit from treatment for a given condition, particularly musculoskeletal disease. Such subjects may include, without limitation, those who have been diagnosed with said condition, those who are likely to develop said condition and / or those in whom said condition should be avoided.
The terms "treat" or "treatment" encompass both the therapeutic treatment of an already developed disease or condition, such as the therapy of an already developed musculoskeletal disease, as well as prophylactic or preventive measures, the purpose of which is to prevent or reduce the chances of occurrence of an undesirable condition, such as for example preventing the onset, development and progression of a musculoskeletal disease.
Beneficial or desired clinical outcomes may include, without limitation, alleviation of one or more symptoms or one or more biomarkers, decrease in the extent of disease, stabilization (i.e. non-aggravation) of the disease state, delay or slowing of the progression of the disease, amelioration or palliation of the disease state, and the like. "Treatment" can also mean prolonging survival over expected survival if one does not receive treatment.
The term "prophylactically effective amount" refers to an amount of an active compound or pharmaceutical agent which inhibits or delays the onset of a disorder in a subject, as desired by a researcher, veterinarian, physician, or physician. another clinician.
The formulations and methods taught herein make it possible to administer a therapeutically effective amount of active pharmaceutical ingredients to subjects suffering from a musculoskeletal disease who will benefit from such treatment.
The term "therapeutically effective amount" as used herein refers to an amount of active compound or pharmaceutical agent which elicits in a subject the biological or drug response desired by a surgeon, researcher, veterinarian, physician, or physician. physician or other clinician, which may include alleviating the symptoms of the disease or condition being treated.
Appropriate therapeutically effective doses of an active pharmaceutical substance or active pharmaceutical ingredient in the present formulation can be determined by a qualified physician with due regard to the nature of the active pharmaceutical substance or active pharmaceutical ingredient, the drug. condition and severity of the disease, as well as the age, size and condition of the patient.
In some embodiments, the musculoskeletal disease can affect tendons and / or ligaments.
In some cases, the pharmaceutical formulation described herein may form part of a combination therapy strategy which is not limited, for example, to other medicinal therapies known to one skilled in the art, or to kinesiotherapy.
In other cases, the lyophilized formulation is used as a measure to prevent the onset of symptoms.
In other cases, bone or joint disease can be classified as progressive bone disease or progressive joint disease. In still other cases, bone or joint disease is a genetic disease or disorder. In still other cases, bone or joint disease is an age-related disease. In yet other cases, the use of the lyophilized formulation is only symptomatic.
It is furthermore a method of treating a musculoskeletal disease in a subject in need of such treatment, comprising administering to said subject a therapeutically or prophylactically effective amount of the pharmaceutical formulation as described above. above. In some cases, the pharmaceutical formulation is administered at multiple times. In other cases, the different administrations are separated from each other by regular time intervals. In other cases, the time intervals between the different administrations increase by a certain multiplicity. In still other cases, the time intervals between different administrations increase exponentially. In some versions, aliquots of a therapeutic dose are administered through separate injection sites.
The present application also presents the aspects and embodiments as set out in the following statements: Statement 1. A lyophilized pharmaceutical formulation comprising plasma proteins or derivatives thereof and hyaluronic acid or a derivative thereof. Herein, wherein the formulation, when reconstituted in an aqueous solution, has a reconstitution time of 15 minutes or less.
Statement 2. The lyophilized pharmaceutical formulation according to statement 1, wherein the formulation further comprises an alpha-2 adrenergic receptor agonist, preferably wherein the alpha-2 adrenergic receptor agonist is clonidine or a derivative thereof. this.
Statement 3. The lyophilized pharmaceutical formulation according to statement 1 or 2, wherein the formulation comprises from about 30% to about 80% by weight of the plasma proteins or their derivatives.
Statement 4. The lyophilized pharmaceutical formulation according to any one of statements 1 to 3, wherein the plasma proteins are solvent / detergent (S / D) treated plasma proteins, preferably human S / D plasma proteins, and / or wherein the hyaluronic acid derivative is a salt of hyaluronic acid, an ester of hyaluronic acid with an alcohol of the aliphatic, heterocyclic or cycloaliphatic series, or a sulfated form of hyaluronic acid.
Statement 5. The lyophilized pharmaceutical formulation according to any one of statements 1 to 4, wherein the hyaluronic acid or a derivative thereof comprises fibers having a molecular weight of 0.2 MDa to 4.5 MDa, from preferably from 0.5 MDa to 1.2 MDa. The lyophilized pharmaceutical formulation according to any one of statements 1 to 5, further comprising at least one salt, preferably a calcium salt, more preferably calcium chloride; and / or further comprising at least one buffering component or one acid component, preferably hydrochloric acid. Statement 7. The lyophilized pharmaceutical formulation according to one of statements 1 to 6, further comprising one or more active pharmaceutical ingredients.
Statement 8. Lyophilized pharmaceutical formulation according to statement 7, wherein the active pharmaceutical ingredient (s) are each independently selected from the group consisting of: a cellular composition, an active pharmaceutical compound, a protein, a peptide and a small organic molecule. .
Statement 9. The lyophilized pharmaceutical formulation according to statement 8, wherein the cellular composition comprises mesenchymal stem cells (MSCs), osteoprogenitors, osteoblast cells, osteocytes, chondroblast cells and / or chondrocytes.
Statement 10. The lyophilized pharmaceutical formulation according to statement 8, wherein the active pharmaceutical protein or peptide is a growth factor, preferably a growth factor selected from the group consisting of fibroblast growth factor (FGF), a growth factor. Transforming Growth Factor Beta (TGFB), Platelet Derived Growth Factor (POGF), Interleukin-8 (IL-8), Bone Morpho-20 Genetic Protein (BMP), Parathyroid Hormone (PTH), parathyroid hormone bound protein (PTHrp) and stem cell factor (SCF); preferably a growth factor chosen from the group consisting of FGF-2, TGFB-1, POGF, IL-8, BMP-2, BMP-4, BMP-6, BMP-7 , PTH, PTHrp and SCF.
Statement 11. The lyophilized pharmaceutical formulation according to any one of statements 1 to 10, further comprising at least one glycosaminoglycan. Statement 12. The lyophilized pharmaceutical formulation according to statement 11, in which one of the additional glycosaminoglycans is chondroitin sulfate.
Declaration 13. The lyophilized pharmaceutical formulation according to one of declarations 1 to 12, further comprising serum, preferably human serum.
Statement 14. The lyophilized pharmaceutical formulation according to any one of statements 1 to 13, further comprising proteins of whole blood or proteins of a fractionated component of whole blood, preferably wherein the whole blood is whole human blood. .
Declaration 15. The lyophilized pharmaceutical formulation according to one of declarations 1 to 14, in which the formulation corresponding to an administration dose comprises -from 1 mg to 100 mg of hyaluronic acid or its derivative, preferably of 2 mg. to 50 mg of hyaluronic acid or its derivative, more preferably from 5 mg to 40 mg of hyaluronic acid or its derivative; and -optionally from 1 µg to 500 µg of the alpha-2-adrenergic receptor agonist, preferably from 2 µg to 250 µg of the alpha-2-adrenergic receptor agonist, more preferably from 5 µg to 125 µg of alpha-2-adrenergic receptor agonist.
Statement 16. The lyophilized pharmaceutical formulation according to one of statements 1 to 15, in which the formulation comprises: -from about 30 to 80% by weight of plasma proteins or their derivatives - from about 5.0% to about 20.0% by weight of hyaluronic acid or a derivative thereof; and optionally -from about 0.01% to about 0.1% by weight of the alpha-2-adrenergic receptor agonist; from about 1.5% to about 3.0% by weight of the salt; and / or -from about 0.1% to about 2.0% by weight of the buffer component or the acid component.
Statement 17. The lyophilized pharmaceutical formulation according to one of statements 1 to 16, in which the lyophilized formulation has a degree of swelling of 9 to 30. Statement 18. The lyophilized pharmaceutical formulation according to one of aspects 1 to 17, which is configured for parenteral administration after reconstitution, preferably for intraosseous, periosseous, intraarticular or periarticular administration, or for intra-tendon, peri-tendon, intraligament or peri-ligament administration after reconstitution.
Declaration 19. A kit of parts comprising: - a lyophilized pharmaceutical formulation according to one of the items 1 to 18; - a syringe comprising an aqueous solution - preferably at least one needle.
Declaration 20. Process for preparing a lyophilized pharmaceutical formulation according to one of declarations 1 to 18, comprising the following steps a) the mixture of plasma proteins or their derivatives, hyaluronic acid or a derivative thereof and an aqueous solution, which makes it possible to obtain a bulk mixture having a concentration of plasma proteins or their derivatives of 20 mg / ml to 50 mg / ml and a concentration of hyaluronic acid or its derivative of 4 mg / ml to 8 mg / ml; b) sterilizing the bulk mixture by steam sterilization or filtration, thereby obtaining a sterile mixture; and (c) lyophilization of the sterile mixture, thereby obtaining the lyophilized pharmaceutical formulation.
The method according to statement 20, wherein step (a) further comprises admixing an alpha-2 adrenergic receptor agonist, a salt and / or a buffering component or an acid component, to obtain a bulk mixture having a concentration of the alpha-2 adrenergic receptor agonist of 20 µg / ml to 35 µg / ml, a salt concentration of 0.5 mg / ml to 1.5 mg / ml and / or a concentration of the buffer component or the acid component of 0.05 mg / ml to 3.0 mg / ml.
Statement 22. The method according to statement 20 or 21, wherein the hyaluronic acid or its derivative comprises fibers having a molecular weight of 0.2 MDa to 4.5 MDa, preferably 0.5 MDa to 1.2 MDa. MDa.
Statement 23. Lyophilized pharmaceutical formulation obtainable or obtained by a method according to any one of statements 20 to 22, preferably the lyophilized pharmaceutical formulation according to any one of statements 1 to 18 obtainable or obtained by a method according to any one of statements. any of statements 20 to 22.
Statement 24. The lyophilized pharmaceutical formulation according to one of statements 1 to 18 or 23, intended for use in the treatment of a musculoskeletal disease, preferably in which the lyophilized pharmaceutical formulation is mixed with an aqueous solution before being used. administered.
Statement 25. The lyophilized pharmaceutical formulation for use according to Statement 24, preferably when the musculoskeletal disease is bone disease or joint disease.
Although the invention has been described in connection with specific representations thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art in light of the foregoing description. Accordingly, it is intended to include all such alternatives, modifications and variations as follows, within the spirit and the broad scope of the appended claims.
The aspects and embodiments of the invention which are disclosed herein are also supported by the following non-limiting examples.
EXAMPLES Example 1 - Method for obtaining a lyophilized pharmaceutical composition according to one embodiment of the invention A bulk mixture was prepared by mixing 5 grams of fibers of hyaluronic acid (HA) (0.6-1 MDa ), 500 ml of water, 1.25 ml of clonidine HCl (clonidine hydrochloride) (20 mg / ml), 476.25 ml of S / D plasma, 10 ml of HCl (1M), and 12.5 ml of CaCl (80 mg / ml). The bulk mixture thus obtained was sterilized by filtration. In a next step, storage vials were filled with 5 ml of the sterilized bulk mixture and then lyophilized. After the freeze-drying phase, the vials were stoppered. Figure 1 shows three vials comprising a lyophilized pharmaceutical formulation according to one embodiment of the invention. The lyophilized formulation was a pale yellow-white cake. Before being injected into a patient in need, the pharmaceutical formulation contained in the storage vials is reconstituted in 2.4 ml of water. Example 2 - Composition of a reconstituted lyophilized pharmaceutical formulation corresponding to an administration dose according to certain embodiments 25 mg hyaluronic acid Plasma S / D 188 mg (S / D lyophilized plasma)
Example 3 - Characteristics of a lyophilized pharmaceutical formulation corresponding to certain embodiments Percentage by weight of material | 61% protein 709 Example 4. Reconstitution time of the various formulations according to certain embodiments
4.1 HA of different molecular weights HA compositions of different molecular weights (high molecular weight (MW): 3.5 - 4.5 MDa, average MW: 0.6 - 1 MDa, low MW: less than 0.6 MDa ) and different dilution factors of hyaluronic acid (see 4.2 below) are produced.
4.2 Different dilution of the bulk mixture Three different bulk mixtures were prepared: Hyaluronic acid fibers (1 g) were mixed with 95.25 ml of S / D plasma, 5 mg of clonidine HCl (0.25 ml of a 20 mg / ml solution), 200 mg of CaCl2 (2.5 ml of an 80 mg / ml solution), 72.92 mg of HCl (2 ml of a 1M solution), to obtain a first bulk mixture (without dilution, called "1x").
In addition, fibers of hyaluronic acid (1 g) were mixed with 100 ml of HZO to obtain a first solution A. Hyaluronic acid fibers (1 g) were also mixed with 200 ml of H2O to obtain a first solution B. A second solution was prepared by mixing 95.25 ml of S / D plasma, 5 mg of clonidine HCl (0.25 ml of a 20 mg / ml solution), 200 mg of CaCL (2.5 ml of an 80 mg / ml solution) and 72.92 mg of HCl (2 ml of a 1M solution). The first solution λ (100 ml) was mixed with the second solution (100 ml) in a ratio of 1: 1 (v / v) to obtain a bulk mixture called "2x". The first solution B (200ml) was mixed with the second solution (100ml) in a ratio of 2: 1 (v / v) to obtain a bulk mixture called Wax!
4.3 Lyophilized wafer The bulk mixtures for each molecular weight (MW) of HA and the dilution are transferred to a vial for lyophilization. The density of the lyophilized product is determined by the weight / volume ratio of the cake. The weight of the cake is obtained by subtracting the weight of the empty vial from the weight of the vial containing the lyophilized cake.
The volume of the cake is calculated using the formula: a x R2x h where R is the radius of the cake and h the height of the cake.
The density of the dried cake decreased with increasing dilution of the bulk mixture before freeze-drying: density (1x)> density (2x)> density (3x) (Table 1). The lyophilized pharmaceutical formulations prepared by dilution had a density of between 0.04 g / cm "and 0.08 g / cm". The density was not influenced by the molecular weight of HA (Table 1). Table 1: Weight (g), volume (cms) and density (g / cm °) of the lyophilized pharmaceutical formulations according to the embodiments of the invention (n = 15); Bulk mixing of the formulations before lyophilization: 1x, 2x, or 3x Ee Parma Ans AE os om [oi route Ge [oe ve EE 1 [sp Toon [num [amp [vos [your [vs (ee [VE [5e [voor [vos [rar [oon (er [oe [5 [Pam [rs [vo [vos [rise [von [voor [ras [an Lyophilized pharmaceutical formulations prepared by a method involving dilution (eg, 2x bulk mixtures and 3x) had optimal density for reconstitution.
Accordingly, lyophilized pharmaceutical formulations prepared by a method comprising dilution (2x or 3x) have been preferred in order to obtain a wafer having a satisfactory density.
Absorption capacity of the cake The absorption capacity of the various lyophilized products was evaluated by measuring the weight of the cake over time.
Briefly, 9.6 ml of water was added to the lyophilized cake to ensure its complete immersion.
The additional water was then removed.
The weight was measured right after removing the extra water.
The process was repeated several times.
Hydration curves plotting weight versus time showed that lyophilized pharmaceutical formulations according to embodiments of the invention were completely hydrated within 30 seconds.
Figure 2 shows a representative hydration curve illustrating weight versus time for five lyophilized pharmaceutical formulations according to one embodiment of the present invention prepared by mixing the first solution and the second solution in a ratio of 1: 1 (v / v) (2x) and with medium molecular weight HA. The lyophilized pharmaceutical formulations were completely hydrated in less than 30 seconds (the first time point after 0 sec was between 17 sec and 22 sec).
By comparing the absorption capacity of lyophilized pharmaceutical formulations as a function of HA molecular weight (low, medium and high MW HA), the hydration capacity of lyophilized pharmaceutical formulations with medium and high MW HA was superior to the hydration capacity of lyophilized pharmaceutical formulations containing low MW HA (data not shown).
The hydration capacity of lyophilized pharmaceutical formulations increases with increasing molecular weight of HA: high HAmweal absorption capacity> Medium HAmw absorption capacity> HAmwraibie absorption capacity The hydration capacity increased with the reduction in density lyophilized pharmaceutical formulations: 3x absorption capacity> 2x absorption capacity> 1x absorption capacity.
Wafer reconstitution time (in water) 2.4 ml of water for injection was added to each sample lyophilized using a syringe (0.1 ml dead volume). After complete hydration of the patty, the vial was mixed between the hands by rolling it (2 to 4 mixing passes) or by shaking it up and down by hand. The mixing only lasted about 30 seconds. Reconstitution time was evaluated using a timer. The reconstitution time began immediately after adding the water and stopped after the product was completely resuspended. Reconstitution was assessed by visual examination. The reconstituted product was a pale yellow to yellow, cloudy and slightly viscous solution. The solution sometimes contained bubbles due to agitation.
The data show that for high molecular weight HAs, homogeneous reconstitution was not possible for all ivophilized pharmaceutical formulations. Reconstitution time analysis was therefore only performed for lyophilized pharmaceutical formulations containing low and medium molecular weight HA.
Table 2: Hydration time (min: sec), mixing time (min: sec) and reconstitution time (min: sec) of the pharmaceutical formulations lyophilized according to the concretizations of the invention (n = 5); Bulk mixing of the formulations before lyophilization: 1x, 2x, or 3x PT th a Time Time | Delay of | Time Time | Time to hydrate | of reconstitutio | of hydration | re-establishment mixag | n n mixag | n e e 1x | Average | 01:43 00:39 | 02:22 06:49 05:19 | 12:08 Mee Oe Ee so a ee 2x | Average | 00:57 00:32 | 01:29 00:55 00:51 | 01:47 ere
BC 3x | Average | 00:42 00:27 | 01:09 00:43 00:51 | 01:34 Mee [De Ee aon [on [en Data show that mass dilution decreased reconstitution time. Similar reconstitution times were obtained when preparing the bulk mixture by mixing the first solution and the second solution in a ratio of 1: 1 (v / v) ("2x") or 2: 1 (v / v ) ("3x") (Table 2). In view of the above data, the lyophilized pharmaceutical formulations prepared with low or medium molecular weight HA and by mixing the first solution and the second solution in a ratio of 1: 1 (v / v) ("2x" ) were preferred in order to obtain a homogeneous formulation for injection in combination with a satisfactory reconstitution time.
4.4 Wafer reconstituted with water Viscosity of the formulation The viscosity was evaluated using a microVISC'M viscometer (RheoSense, CA, USA) according to the supplier's method. Before each use of the microVISC "", the viscosity of a reference oil was measured to assess the calibration of the equipment. The HB02 sensor cartridge was first placed in the viscometer. Then 400 µl of sample were loaded into the disposable pipette that was mounted on the viscometer.
The advanced parameters were: - Shear rate = 111.6 s! - Measurement volume = 30 ul - Priming volume = 15 ul - Pause time = 5s - Sensor range = 60 to 5000 cP Temperature being a well-known parameter which influences viscosity, each measurement must be carried out at 25, 0 + 0.1 ° C. The measurement chip contained a rectangular slotted flow channel of borosilicate glass, with a uniform cross section. The sample was injected at a constant rate through the flow channel where multiple pressure sensors mounted in the base monitor the pressure drop from inlet to outlet. The pressure drop was correlated with the shear stress at the boundary wall. The shear rate and shear stress were directly related to the geometry of the rectangular slot and the flow rate, allowing viscosity to be measured. A VROC® chip assessed viscosity by measuring the pressure drop when a test liquid flowed through its rectangular slit microfluidic channel. Based on the Hagen-Poiseuille flow, this is a well-known application of rheometric principles (K. Walters, Rheometry, Chapman and Hall, London, 1975), which is also listed in the American Pharmacopoeia. The viscosity data were exported into the microVISC "" control 2.0 software. The results of the viscosity measurements are provided in Table 3. Table 3: Viscosity (cP), scale (%) and R ° of the lyophilized pharmaceutical formulations according to the embodiments of the invention (n = 5); bulk mixing of the formulations before lyophilization: 1x, 2x, or 3x | HA MW low HA MW medium HA MW high
11.277 0.982 | 314.4 1,000 | 725.0 | 58,920 | 0.995 | [SD | 3.865 0.015 0.000 | 1158 9.356 | 0.004
8.085 0.989 | 278.9 1,000 | 863.1 | 75,900 | 0.999
6.944 0.992 | 266.1 1,000 | 763.2 | 67.020 | 0.993 | [SD | 1.332 0.009 0.000 | 1218 13.283 | 0.007
The viscosity increased with the weight of HA MW: viscosityHAmwhigh> viscosityHAmwmean> viscosityHAmwraibie. An optimum viscosity for injection of between 200 cP and 500 cP was found for reconstituted formulations containing medium molecular weight HAs.
The viscosity was not influenced by other parameters such as the dilution of the bulk mixture. In conclusion, the lyophilized pharmaceutical formulation containing medium molecular weight HA and prepared by mixing the first solution and the second solution in a ratio of 1: 1 (v / v) ("2x") had a reconstitution time. satisfactory, while having a viscosity after reconstitution which allows both easy administration by injection and sufficient lubricating action after administration. Protein content The protein content was determined by a colorimetric test using a commercial kit (Detergent Compatible Protein assay kit from Biorad, ref # 500-0116) on the basis of the manufacturer's recommendations. Briefly, a standard curve with dilutions of protein standard solutions (Biorad, Quick Start Bovin Serum Albumin Standard, # 500-020) was performed. Five µl of reconstituted standard and wafer solutions were placed in the well of a clean, dry microplate and 25 µl / well of Reagent A was added. Then 200 µl of Reagent B was added and the microplate was stirred for 5 seconds. After a 15 minute incubation, the plates are red at 620 nm. The results of the protein concentration measurements are provided in Table 4. Table 4: Protein concentration (mg / ml) of the lyophilized pharmaceutical formulations according to the embodiments of the invention (n = 5); bulk mix of formulations before lyophilization: 1x, 2x, or 3x LU) HA MW low HA MW medium HA MW high
53.16 53.95 48.35 DE WE er
50.43 45.24 40.59 DE a am
48.99 50.08 50.70
BE The plasma protein concentration averaged 50 mg / ml. Thus, each ivophilized formulation contained approximately 120 mg of plasma protein (equivalent to 50 mg / ml x 2.4 ml of reconstitution volume). The total weight of the lyophilized formulation was about 200 mg and therefore each vial contained about 60% by weight of plasma protein.
The variability between samples and between different conditions may be related to the experiment itself (for example, the weight of the starting material).

权利要求:
Claims (15)
[1]
AMENDED CLAIMS l. A lyophilized pharmaceutical formulation comprising lyophilized plasma and hyaluronic acid or a derivative thereof, wherein the hyaluronic acid or a derivative thereof has a molecular weight ranging from 0.6 MDa to 1.0 MDa. , and the lyophilized formulation has a density of between 0.04 g / cm 2 and 0.08 g / cm}, wherein the formulation, when reconstituted in an aqueous solution, has a reconstitution time of 15 minutes or less and is configured for injection.
[2]
2. Lyophilized pharmaceutical formulation according to claim 1, wherein the reconstituted pharmaceutical formulation is characterized by a viscosity of between 200 cP and 500 cP; preferably with a viscosity of between 250 cP and 400 cP.
[3]
3. Lyophilized pharmaceutical formulation according to claim 1 or 2, wherein the formulation further comprises an alpha-2 adrenergic receptor agonist, preferably wherein the alpha-2-adrenergic receptor agonist is clonidine or a derivative thereof. - this.
[4]
4 lyophilized pharmaceutical formulation according to one of claims 1 to 3, wherein the formulation comprises 30% to 80% by weight of plasma proteins.
[5]
5. A lyophilized pharmaceutical formulation according to any one of claims 1 to 4, wherein the plasma proteins are solvent / detergent (S / D) treated plasma proteins, preferably human S / D plasma proteins, and / or in wherein the hyaluronic acid derivative is a salt of hyaluronic acid, an ester of hyaluronic acid with an alcohol of the aliphatic, heterocyclic or cycloaliphatic series, or a sulfated form of hyaluronic acid.
[6]
6. A lyophilized pharmaceutical formulation according to any one of claims 1 to 5, further comprising at least one salt, preferably a calcium salt, more preferably calcium chloride; and / or further comprising at least one buffering component or one acid component, preferably hydrochloric acid.
[7]
7. Lyophilized pharmaceutical formulation according to one of claims 1 to 6, in which the formulation corresponding to an administration dose comprises - from 1 mg to 100 mg of hyaluronic acid or its derivative, preferably from 2 mg to 50 mg of hyaluronic acid or its derivative, more preferably from 5 mg to 40 mg of hyaluronic acid or its derivative; and
- optionally from 1 μg to 500 μg of the alpha-2-adrenergic receptor agonist, preferably from 2 μg to 250 μg of the alpha-2-adrenergic receptor agonist, more preferably from 5 μg to 125 μg of the alpha-2-adrenergic receptor agonist.
[8]
8. A lyophilized pharmaceutical formulation according to any one of claims 1 to 7, wherein the formulation comprises - 30 to 80% by weight of plasma proteins - 5.0% to 20.0% by weight of hyaluronic acid or d. a derivative thereof; and optionally - 0.01% to 0.1% by weight of the alpha-2-adrenergic receptor agonist; - 1.5% to 3.0% by weight of the salt; and / or - 0.1% to 2.0% by weight of the buffer component or of the acid component.
[9]
9. A kit comprising: - a lyophilized pharmaceutical formulation according to one of claims 1 to 8; - a syringe comprising an aqueous solution; and - preferably, at least one needle.
[10]
10. A process for preparing a lyophilized pharmaceutical formulation according to any one of claims 1 to 8, comprising the following steps (a) mixing plasma and hyaluronic acid or a derivative thereof, which makes it possible to d '' obtain a bulk mixture, in which the hyaluronic acid or a derivative thereof has a molecular weight ranging from 0.6 MDa to 1.0 MDa: (b) sterilization of the bulk mixture by steam sterilization or by filtration, which makes it possible to obtain a sterile mixture; and (c) [yophilization of the sterile mixture to obtain the lyophilized pharmaceutical formulation; wherein step (a) comprises the steps of (a1) dissolving hyaluronic acid or its derivative in an aqueous solution, thereby obtaining a first solution; (a2) preparing a second solution comprising the plasma and, optionally, an alpha-2 adrenergic receptor agonist, and (a3) mixing the first and the second solution to obtain the bulk mixture, in which the first solution and the second solution are mixed in a ratio of at least 1: 1 (v / v).
[11]
11. The method of claim 10, wherein the bulk mixture has a plasma protein concentration of 20 mg / ml to 50 mg / ml and a concentration of hyaluronic acid or a derivative thereof of 4 mg / ml. ml to 8 mg / ml.
[12]
12. The method of claim 10 or 11, wherein step (a) further comprises admixing an alpha-2-adrenergic receptor agonist, a salt and / or a buffering component or an acidic component, thereby obtaining a bulk mixture having a concentration of the alpha-2 adrenergic receptor agonist of 20 µg / ml to 35 µg / ml, a salt concentration of 0.5 mg / ml to 1.5 mg / ml and / or a concentration of the buffer component or the acid component of 0.05 mg / ml to 3.0 mg / ml.
[13]
13. Lyophilized pharmaceutical formulation obtainable or obtained by a process according to any one of claims 10 to 12, preferably a lyophilized pharmaceutical formulation according to any one of claims 1 to 8 obtainable or obtained by a process according to any one of claims 1 to 8. any of claims 10 to 12.
[14]
14. Lyophilized pharmaceutical formulation according to one of claims 1 to 8 or 13, for use in the treatment of a musculoskeletal disease.
[15]
15. Lyophilized pharmaceutical formulation according to one of claims 1 to 8, 13 or 14, wherein the lyophilized pharmaceutical formulation is mixed with an aqueous solution before administration.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BE1021755B1|2016-01-15|FORMULATIONS COMPRISING SOLVENT / DETERGENT-TREATED PLASMA | AND USES THEREOF

---

Alcaraz et al.2019|Extracellular vesicles from mesenchymal stem cells as novel treatments for musculoskeletal diseases

---

Kim et al.2014|Novel osteoinductive photo-cross-linkable chitosan-lactide-fibrinogen hydrogels enhance bone regeneration in critical size segmental bone defects

---

Maisani et al.2018|A new composite hydrogel combining the biological properties of collagen with the mechanical properties of a supramolecular scaffold for bone tissue engineering

---

KR20160147058A|2016-12-21|Therapeutic placental compositions, methods of making and methods of use

---

AU2016321448A1|2018-03-15|Cell expansion methods and therapeutic compositions

---

Wu et al.2019|Exosomes secreted by stem cells from human exfoliated deciduous teeth promote alveolar bone defect repair through the regulation of angiogenesis and osteogenesis

---

Xing et al.2020|Emerging role of exosomes in craniofacial and dental applications

---

Lopez-Lacomba et al.2006|Use of rhBMP-2 activated chitosan films to improve osseointegration

---

BE1027216B1|2021-06-21|ENHANCED LYOPHILIZED FORMULATIONS INCLUDING HYALURONIC ACID AND PLASMATIC PROTEINS, AND THEIR USES

---

US20120328578A1|2012-12-27|Primed stem cells and uses thereof to treat inflammatory conditions in joints

---

Chung et al.2019|Fat grafting into younger recipients improves volume retention in an animal model

---

Alsousou et al.2017|Platelet-rich plasma in regenerative medicine

---

Cheng et al.2020|Influence of human platelet lysate on extracellular matrix deposition and cellular characteristics in adipose-derived stem cell sheets

---

BE1023315B1|2017-02-01|In vitro preservation of therapeutic cells

---

US20130251690A1|2013-09-26|Stem cell differentiation using keratin biomaterials

---

US20180000869A1|2018-01-04|Amniotic fluid-derived preparations

---

Chen et al.2020|Efficacy of biologics for ligamentous and tendon healing

---

BE1026595A1|2020-04-01|METHODS FOR DIFFERENTIATION OF MESENCHYMAL STEM CELLS

---

CN114173793A|2022-03-11|Composition, kit and use thereof

---

CN114080220A|2022-02-22|Method for preparing gel-forming composition

---

EP2552463B1|2017-08-16|Proangiogenic compositions, method for preparing them, and uses thereof

---

FR3053592A1|2018-01-12|STABLE LIQUID FIBRINOGEN

---

Hammers2012|Influence of insulin-like growth factor-I on skeletal muscle regeneration

同族专利:

---

公开号 | 公开日

---

TW202108128A|2021-03-01|

---

BE1027216A1|2020-11-18|

---

KR20220008289A|2022-01-20|

---

CN113825498A|2021-12-21|

---

CA3137246A1|2020-11-19|

---

IL287987D0|2022-01-01|

---

WO2020229526A1|2020-11-19|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

KR101366451B1|2013-01-14|2014-02-24|순천향대학교 산학협력단|Method of bcp scaffold which hyaluronic acid/gelatin-10% bcp hydrogel is loaded for bone regeneration|

---

CN104587525A|2014-12-19|2015-05-06|深圳中元生物科技有限公司|Scaffold containing platelets and hyaluronic acid and preparation method of scaffold|

---

WO2017218942A1|2016-06-16|2017-12-21|Eye Care International, Llc|Compositions and methods of treating dry syndrome and other traumatized non-keratinized epithelial surfaces|

---

US5837539A|1990-11-16|1998-11-17|Osiris Therapeutics, Inc.|Monoclonal antibodies for human mesenchymal stem cells|

---

US5811094A|1990-11-16|1998-09-22|Osiris Therapeutics, Inc.|Connective tissue regeneration using human mesenchymal stem cell preparations|

---

US5486359A|1990-11-16|1996-01-23|Osiris Therapeutics, Inc.|Human mesenchymal stem cells|

---

US5972703A|1994-08-12|1999-10-26|The Regents Of The University Of Michigan|Bone precursor cells: compositions and methods|

---

US5736396A|1995-01-24|1998-04-07|Case Western Reserve University|Lineage-directed induction of human mesenchymal stem cell differentiation|

---

US5827740A|1996-07-30|1998-10-27|Osiris Therapeutics, Inc.|Adipogenic differentiation of human mesenchymal stem cells|

---

WO2000007639A1|1998-08-07|2000-02-17|Tissue Engineering, Inc.|Bone precursor compositions|

---

CA2882317C|2012-09-26|2021-04-06|Bone Therapeutics S.A.|Formulations comprising solvent/detergent-treated plasma and hyaluronic acid for treating musculoskeletal diseases|

---

法律状态:
2021-07-19| FG| Patent granted|Effective date: 20210621 |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP19174129|2019-05-13|

---